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" When the patient dies the kidneys may go to the
pathologist, but while he lives the urine is ours. It can
provide us, day by day, month by month, year by year,
with a serial story of the major events going on within
the kidney.
The examination of the urine is the most essential




Urolithiasis is a condition known to Man for
centuries, which once established, frequently pursues a
recurring course. This might suggest a chronic
underlying abnormality yet often no definite
predisposing cause is found. Abnormalities in the urine,
serum or renal histology of stone-forming patients are
claimed by some to be aetiologically important while
others continue to dispute this.
This thesis comprises a review of previous work, an
account of a prospective study carried out by the author
on a group of stone formers to address this problem and
a discussion of the results obtained.
Synopsis:
Prior to the advent of an extra corporeal
shock wave lithotripsy service (ESWL) in Scotland in
1986, most kidney stones were treated by percutaneous
nephrolithotomy (PCN). This procedure provided an ideal
opportunity to biopsy the kidney allowing renal
histology and the degree of microscopic renal
calcification to be assessed and compared with control
material. The biopsy findings of individual patients
were considered in relation to subsequent serum and
urinary biochemical data. As the relative importance of
various urinary risk factors pertaining to stone
formation remains controversial, assessment of 24hr
urine excretion of Calcium, Urate, Oxalate, Citrate and
Creatinine, serum concentrations of Urea, Creatinine,
Calcium and Urate and blood gas analyses were also
undertaken in this group of stone formers. A group of
non - stoneforming adult out-patients acted as controls.
Statistical analysis of all data was performed
comparing the study group results both with our own
controls as well as with other series.
This has allowed us to form conclusions about the
process of stone formation and to develop a plan for the
rational investigation and management of patients
presenting with urinary tract calculi in this area.
SURVEY OF PREVIOUS WORK
Urinary tract calculi have been a cause of pain and
morbidity at as far back as Egyptian times, the pattern
and cause of stone formation being a subject for
speculation and investigation for as long as records have
been kept. Hippocrates noted that patients suffering from
bladder or kidney stones often had "sand" in their urine
and postulated that this resulted from the presence of
Lime in the drinking water. Historical survey of the
theories and results of later researchers (Butt 1956)
reveals that by the 16th century, Jean Baptiste van
Helmont had declared that stone formation resulted from
excretion of an abnormal substance in the urine; the
following century in 1684, Anton van Heyden had
discovered something of the structural complexity of
stones noting that removal of the crystalline component
of a calculus left an underlying insoluble "framework".
By the 1800's, chemical analysis of stones was well
established and several different types of stone were
recognised:- Calcium Carbonate, Phosphate of Lime,
Oxalate of Lime, Ammonium Magnesium Phosphate, Uric Acid
and Cystine. In addition, Meckel von Hemsbach had
recorded that "stone formation depended on encrustation
of an organic substance by precipitable material" and
with the advent of diagnostic X-rays, the increased
incidence of stones in paraplegic and spinal injury
patients and the association of stone formation with
urinary stasis and infection was beginning to be
recognised.
The anatomical location of stones within the urinary
tract, shows a definite historical and socio-economic
trend. Unlike the majority of present day stones which in
80% of cases present in the upper tract and progress
distally in due course (provided the stone is small
enough to pass), the urinary tract stone of former times
was often a bladder stone de novo. Stones within the
bladder have tended to occur most often in young boys in
underdeveloped agricultural societies (Andersen 1973) and
the removal of such calculi by the early Lithotomists is
well described. As countries became more civilised and
industrialised giving way to a more affluent society, the
incidence of lower tract stones decreased and upper tract
stones began to predominate.
The incidence of upper tract stones continues to
increase in the Western world, Sallinen (1959) and
Andersen (1966 and 1972) reporting an increased incidence
in the first half of this century of 100% and 200% in
Finland and Norway respectively; the prevalence has been
previously assessed as 5-10% (Scott 1977, Tschope 1981,
Sierkowski 1978), Smith observing in 1989 that by the age
of 70 years 5% of females and 12% of males can expect to
have had renal colic.
The urinary calculus is a complex structure composed
of one or more crystalline substances associated with a
variable proportion of organic matrix material, the
latter usually accounting for less than 10% of the dry
stone weight.
The commonest age of presentation of stone disease
is from the 3rd to the 5th decade and there is an overall
male preponderance of 2:1, which increases to 3:1 when
only Calcium containing stones are considered and to 5:1
when only the so called "idiopathic calcium stones" are
studied. As Females in the above age band are mostly
between the menarche and the menopause it may be that the
difference in prevalence between the sexes is related to
Oestrogen or secondarily to Citrate excretion, (see
below). If primarily infective stones and those caused by
confirmed Metabolic disorders such as Hyperparathyroidism
or Cystinuria, are excluded from further discussion, the
commonest stone type is that composed of Calcium Oxalate
(with a small proportion of Calcium Phosphate) and this
type comprises 60-80% of most series. Described as
"idiopathic" because no single predisposing cause has
been identified, (although many environmental factors
contribute), this stone is almost exclusively the domain
of the young adult male, the condition pursuing an often
recurring course throughout life, (Henneman 1958, Pak
1974, Rose 1976.)
It is generally believed that a Calcium Oxalate
calculus develops within the kidney at a time when
conditions are favourable and it may be pertinent to
review theories of stone formation at this juncture.
Firstly, the terminology needs to be defined when the
solid phase of a stone salt is in equilibrium with the
liquid phase, that concentration is described as the
"saturation concentration". A less concentrated solution
is said to be "undersaturated" whilst a more concentrated
solution is described as "supersaturated". The
"oversaturation concentration" is the maximum
concentration which can be achieved without the
occurrence of spontaneous precipitation, the product of
the concentration of the relevant ions being called the
"Formation Product". The range of concentrations
intermediate between "saturated" and "supersaturated" is
the "metastable region".
According to Pak (1969) and Robertson (1972), the
urine needs to be supersaturated with respect to the
specific ions comprising the stone before stone formation
can occur.





The first of these refers to the formation of the
smallest unit lattice of a crystal species and can be
homogeneous or heterogeneous. In the case of the former,
the contributing ions are "pure" while in the latter, the
presence of a foreign body such as Collagen or a
different crystal type can artificially lower the
Formation Product allowing crystallization to occur. This
latter process called Epitaxy was described by Lonsdale
(1968) and Meyer et al (1975) although some other workers
would question the validity of this theory. The observed
association of Hyperuricosuria and Calcium
Nephro-lithiasis was attributed to this phenomenon by
Smith and Boyce in 1969 and also by Coe in 1974.
"Crystal Growth" is the process of enlargement of a
nucleated crystal and also requires supersaturation
conditions to be met thereby providing a setting for
promoters or inhibitors to exert their effects.
"Crystal Aggregation" refers to the combination of a
number of crystals to form the crystalline component of a
calculus.
The rate of crystal growth in vitro has been shoton
to be proportional to the degree of supersaturation of a
solution. In vivo, examination of freshly voided urine
showed that crystalluria was more common in stoneformers
than controls and that crystals passed by stoneformers
were larger and more aggregated (Robertson 1969). Smith
(1976) also noticed the passage of large aggregated
crystals in 90% of stoneformers observing similar
findings in only 20% of controls. The finding by
Robertson (1972) of excess numbers of Calcium Oxalate
crystals even in the calyceal urine of stoneformers
suggests a proximal renal site for the initial event. It
is assumed that there is some mechanism whereby an
enlarged crystal becomes trapped during transit along the
urinary tract allowing it to act as a nidus for further
stone deposition, rather than being washed out in the
urine before this can occur, but the mechanism for this
remains unclear. In practice the two most consistently
reported factors affecting stone formation are
i) The extent of urine saturation with a particular
stone salt
(Robertson 1968/71, Finlayson 1969, Pak 1969)
ii) The concentration of protective Inhibitors and
Promoters.
Thomas (1959) carried out in vitro experiments on
the relative mineralizing properties of urine from
stoneformers and controls; Fleisch (1962) isolated
Pyrophosphate as an inhibitor of Calcification in urine
and Meyer (1975) found evidence of a natural crystal
growth inhibitor in Calcium Oxalate stoneformers' urine.
In 1977, Ito and Coe identified an acid peptide / poly¬
ribonucleotide which they claimed was a potent inhibitor
of crystal growth.
It has been frequently observed that stoneformers of
a particular salt type have high urinary concentrations
of one or more ions determining precipitability. Cystine
stone formers excrete large amounts of Cystine in the
urine (Harris,1953), (Dent,1955), (Crawhall,1969). Uric
acid stoneformers have either a low urinary pH or excrete
great quantities of insoluble Uric Acid (Metcalf- Gibson,
1965). Patients with infective (Struvite) stones which
contain Ammonium, are frequently found to harbour
bacteria which can split Urea in urine with the formation
of Ammonia and a high urine pH. (Stamey 1972),(Griffith
1976).
With Idiopathic Calcium stoneformers, however, the
picture is less clear-cut. According to some, firstly
Flocks in 1939/40, followed by Albright and Henneman in
1953, with others since, (Hodgkinson and Pyrah 1958,
Bulusu 1970, Hodgkinson 1978), most recently including
Nikkila in 1989, this group of stoneformers excrete
greater amounts of Calcium and/or Oxalate in the urine
compared with Controls. Lemann (1989) stated that 50% of
stoneformers had urine Calcium greater than two standard
deviations above the Mean control value. Others disagree,
Robertson (1977) noting a considerable overlap between
stoneformer and Control urinary Calcium levels suggesting
that in addition to absolute urinary Calcium or Oxalate
levels, other factors were involved as well. Welshman and
McGeown (1975), Tiselius (1978) and Ryall (1983),
however, could not detect a difference between
stoneformers and controls.
The many epidemiological studies carried out world
wide have established what environmental features
predispose to stone formation. A low urine volume will
tend to promote high super - saturation levels of Calcium
Oxalate and has been shown to occur where input is low or
in hot seasonal or climatic conditions where output falls
as a result of skin losses. This would explain the
seasonal variation in stone incidence noted in Australia
and USA. Frank (1959) and Pierce (1945) observed an
increased incidence of Urolithiasis amongst Israeli and
American troops respectively when stationed in desert
conditions. Parry (1975) however showed that as well as
causing low urine volume, transfer to a hot, sunny
climate was also followed by significantly increased
urinary Calcium excretion. Vitamin D3 is synthesised in
skin exposed to sunlight, and is known to facilitate
absorption of Calcium (and, indirectly, Oxalate) from the
gut lumen. Hot climatic conditions can therefore promote
stone formation in two ways. The importance of adequate
hydration was stressed by Bek-Jensen in 1989 reporting
that 25% of a series of Scandinavian stoneformers had
24hr urine volumes of less than 1000 ml.
It has also been shown that increasing affluence,
social status and some occupations are all positively
(but not necessarily independently) correlated with stone
formation (Robertson 1981). All the above factors may
simply reflect a more refined diet with a higher content
of animal protein and dairy produce; Robertson has shown
that such a diet leads to increased urinary levels of
Calcium, Oxalate and Urate and feels that this factor
alone could account for the observed increased prevalence
of Urolithiasis in this section of the population. Other
workers, however, have been unable to confirm this
association between dietary animal products and
Urolithiasis. (Griffith 1981 and Power 1984)
It has been suggested in the past that as the
prevalence of Urolithiasis in Negro populations compared
with Caucasian races is very low, a racial or ethnic
factor must exist. This has been refuted by Quinland
(1945) who showed that the incidence of stone disease in
Blacks became similar to Whites when they assumed a
Western-style diet.
In summary therefore the major risk factors for
idiopathic stone formation which can be identified
epidemiologically, include being an adult male, leading
an affluent life style, with a diet rich in animal
protein and dairy produce and living in a relatively hot
sunny climate where either as a result of ambient
temperature or simply from consumption of too small a
volume of liquid, the urine output is less than one litre
per day.(Blacklock 1969)
Discussion of physio-pathological risk factors
relating to calculus formation requires a careful
appraisal of the source of origin, the renal handling and
excretion of the various substances thought to be
relevant. With idiopathic Calcium stones the metabolism
of Calcium and Oxalate clearly merits close examination,
however, the role of other suspected promoters or
inhibitors such as Urate, Magnesium, Citrate or
Mucoproteins must also be assessed.
Finally the histopathology of the normal and stone
bearing kidney as evidenced from our own results as well
as by review of the literature will be examined to
establish whether there exists any demonstrable
abnormality amongst recurrent stone formers which might
predispose to calculus formation.
CALCIUM
Calcium is derived mostly from dairy produce in the
diet the net amount produced by endogenous bone breakdown
in a healthy individual being minimal. Absorption from
the lumen of the small gut is active to a large extent
and dependant upon the influence of vitamin D3. Flux can
proceed in either direction across the bowel, the net
transfer being about 0.1 mmol/kg/24hr. Binding within the
lumen of the bowel to Phosphate or fatty acids may
restrict the availability of ionic Calcium for
absorption. The amount of dietary Calcium available for
absorption is increased by the presence of refined
Carbohydrate in the form of Sucrose in the diet
(Wasserman and Taylor 1969) as well as by the presence of
animal protein, (Wasserman et al, 1956). Such an enriched
diet was reported to cause hypercalciuria by Hodgkinson
(1965) and Lindemann (1967). Lemann (1969) demonstrated
an acute rise in urinary Calcium excretion after a
dietary sugar bolus and Macleod and Blacklock (1979)
showed a rise in Calcium absorption from the gut
following ingestion of Sucrose, although these were short
term studies.
According to Andersen (1973) and Robertson (1978),
the increasing dietary content of animal protein in the
last 20 years is the major risk factor for calcium stone
formation. The high protein/low fibre diet which
characterizes the modern Western affluent lifestyle would
seem to promote the absorption of dietary cations such as
Calcium, perhaps because of the reduced amount of phytic
acid which might otherwise form insoluble complexes with
Calcium, preventing absorption, (James et .al 1978) .
Generally, 20% of dietary Calcium is absorbed by a
combination of active transport and passive diffusion,
the fraction absorbed by diffusion increasing with
dietary Calcium content (Wilkinson 1976). At the kidney,
60% of plasma Calcium is filtered (250mmol/24hr) of which
most is actively reabsorbed, 90% of reabsorption taking
place in the proximal tubule linked to Sodium
reabsorption. Factors preventing Sodium reabsorption such
as Sodium load or loop diuretic e.g. Frusemide, reduce
Calcium resorption at this site. A much smaller amount of
Calcium resorption occurs in the distal nephron (distal
convoluted tubule and collecting duct) where Sodium and
Calcium movement are not linked. In fact Thiazide
diuretics produce a Natriuresis without a Calciuresis
inducing a further distal tubular resorption of
Calcium. (Stewart 1981)
Of great interest in relation to stone disease is
the finding by some workers of abnormally high urinary
excretion of Calcium in about 60% of stone formers,
especially in Males. This so called idiopathic
hypercalciuria is not associated with a raised serum
Calcium and was first reported by Flocks (1940) and later
by Hennemann (1958) who also observed an exaggerated
calciuresis in this group of stone formers when
challenged by an increase in dietary Calcium. It is
perhaps surprising that whilst some workers are adamant
that significant hypercalciuria is found in most
idiopathic stoneformers (Hodgkinson,1978) yet others have
found this not to be so. (Welshman and McGeown 1975,
Tiselius 1978, Ryall 1983) It may be that this confusion
arises from difficulty in defining normal values for
Calcium excretion. It is known that the distribution of
Calcium excretion in normal non stone forming individuals
is non - Gaussian, there being significant numbers of
apparently normal individuals with very high values. The
generally accepted normal values (Hodgkinson 1958) for
the U.K. are <7.5 mmols/24hr (adult males) and <6.25
mmols/24hr (adult females). Assuming that idiopathic
hypercalciuria is a reality, there has been considerable
argument especially in North America as to whether this
excess Calcium derives from over-absorption from the
gut,"absorptive" as described by Pak in 1987 and Lemann
in 1989 or because of a low renal threshold, "renal
leak", a view held by Muldowney (1980). Current opinion
favours increased absorption of Calcium from the gut as
being the primary event in most cases. In addition
idiopathic stoneformers are said to show an exaggerated
Calciuresis in response to a dietary Calcium load, (Pak
1974/75). So called "renal hypercalciuria" requires an
unspecified renal tubulopathy causing impaired resorption
of Calcium, secondary hyperparathyroidism and as a result
secondary hyperabsorption of Calcium from the gut. In
fact these artificial divisions are probably
oversimplified since if there was an obligatory renal
leak, treatment in the past of such individuals with a
Calcium gut binder e.g. Sodium Cellulose Phosphate (Dent
1964) would have caused severe demineralisation of the
skeleton to maintain Calcium balance. Conversely if
obligatory hyperabsorption from the gut was the causative
factor in a given individual, treatment on an empirical
basis with a Thiazide diuretic which reduces
hypercalciuria by promoting Calcium resorption in the
distal nephron,(Yendt 1970) would as a result have caused
dangerous hypercalcaemia. As neither of these outcomes
has been reported the matter remains undecided. A
practical policy in the management of Calcium stone
disease with manifest hypercalciuria, (having excluded a
primary hypercalcaemic cause) would be to increase fluid
consumption until a urine output of 3 litres/24hr is
achieved. In view of the association between dietary
Calcium and hypercalciuria, animal protein and dairy
produce should be restricted and in addition Oxalate
containing foods should also be cut down as a result of
the overabsorption which follows Calcium restriction (see
below). If recurrent stone episodes continue despite
these measures then treatment using Thiazides or Sodium
Cellulose Phosphate would be indicated, (Pak 1974),
(Hallson and Rose 1976), (Backman 1980). There has been
some discussion in the literature recently regarding the
possible attenuation of the hypocalciuric effect of
Thiazides when used on a long term basis. In theory
Thiazide should only be effective in renal
hypercalciuria. Preminger in 1987 showed that the
treatment of absorptive hypercalciuria with Thiazides was
transient, attenuation of the initial improvement
occurring over the subsequent two years. Conversely,
similar treatment of renal hypercalciuria patients showed
that the improvement was maintained indefinitely.
OXALATE
Oxalate is a substance which while found widely in
the plant kingdom where it is useful in the formation of
a supporting exoskeleton, is of little or no benefit to
animals. It cannot be metabolised in Man thus any Oxalate
which is absorbed from the diet or synthesised as a
product of metabolism can only be eliminated from the
body by excretion in the urine, where in view of the
extreme insolubility of its Calcium salt, Calcium
Oxalate, crystalluria and stone formation are not
uncommon. Whether or not this occurs depends on the
amount being excreted, the urinary volume and the
relative concentrations of inhibitors of crystalluria
which are present.
While the Oxalate content of some foods is known to
be raised, e.g. Tea, Nuts and certain green vegetables, a
recent paper by Brinkley, Gregory and Pak (1990) stresses
that in relation to Nephrolithiasis, bioavailability as
well as content must be considered. Their study of the
content and bioavailability of Oxalate in tea (with or
without milk), turnip greens, okra, peanuts and almonds
concludes that overall, only nuts present a significant
risk of raising Oxalate excretion in the urine. Robertson
in 1979 showed a relationship between urinary Oxalate and
dietary protein content, however, this was not
substantiated in a recent report by Marangella in 1989.
Normally urinary Oxalate excretion is less than 0.45
mmol/24hr. Hyperoxaluria exists when larger amounts are
present in the urine daily, either as a result of an
inborn error of metabolism (Primary Hyperoxaluria) or as
a secondary phenomenon such as unusual dietary intake or
small bowel disease or surgery leading to increased
absorption from the gut. The commonest form of Primary
Hyperoxaluria arises from the absence in the liver of the
peroxisomal enzyme, Alanine - glyoxylate aminotransferase
resulting in the presence in the urine of large amounts
of Oxalate (0.8-4.0 mmol/24hr) as well as the metabolite
Glycollate ( >0.33 mmol/L). In secondary Hyperoxaluric
states the urine excretion seldom exceeds 1.0 - 1.5
mmol/24hr. and in these circumstances, Glycollate is not
raised.
Some workers believe that the way in which Oxalate
is handled is at least as important as that of Calcium
excretion with respect to idiopathic stone formation.
Robertson (1968) observed that while stoneformers' urine
was generally more concentrated with Calcium than
Controls the increase was not sufficient to cause
spontaneous crystallisation. Moderate increases in
urinary Calcium concentration caused no increase in
Calcium Oxalate crystalluria. Similar increase in urinary
Oxalate levels, however, caused significant increase in
Calcium Oxalate crystalluria, suggesting that Oxalate
might be more important than Calcium in this respect. The
sources of origin of urinary Oxalate are less well
understood than for Calcium. It is known that only 5-10%
of Oxalate present in the gut is normally absorbed,
possibly because it is complexed with Calcium in the
lumen and passes out unchanged. Furthermore the amount of
intraluminal Calcium determines the percentage of Oxalate
absorbed there being an inverse relationship between
ingested Calcium and Oxalate absorption. (Williams and
Wandzilak 1989) . In conditions of small bowel pathology
or following small bowel resection this figure may rise
to 60%. This enteric hyperoxaluria is thought to be due
to Calcium being bound to unabsorbed long chain fatty
acids and as a result Oxalate remains un-complexed and
thus available for absorption. In a similar way enhanced
uptake of Oxalate occurs following dietary restriction of
Calcium. Another suggested cause of enteric hyperoxaluria
is the excessive absorption of Oxalate from the colon as
a direct result of mucosal change caused by the presence
of unresorbed bile acids, (Dobbin 1976). In addition to
gut absorption, urinary Oxalate is partly derived from
endogenous metabolism although the absolute amount
forming via glycine or ascorbic acid pathways is
controversial (Hodgkinson 1977). Rose (1988) concludes
that endogenous production is only significant on a low
Oxalate diet and points out the errors that may have
previously arisen by assuming that Oxalate identified in
the urine had derived from Ascorbate metabolism in vivo
when in fact Ascorbate in urine converts spontaneously in
vitro at alkaline pH (Rose 1985). It follows therefore
that in the past, spuriously high Oxalate level may have
been recorded from 24hour urine collections not acidified
ab initio.
Oxalate reaches the urine both by filtration and
tubular secretion and given favourable conditions of
osmolality and pH forms typical octahedral crystals
(envelope crystals) characteristically of 2-10um in size
although large crystals >100um across have been
described. It is said by some that the smaller crystals
are common in normal individuals and that the larger
sized crystals are found only in stone formers, perhaps
as a result of a deficiency of inhibitors (Robertson et
al 1969) . These crystals remain discrete by virtue of
mutually repulsive electrostatic potentials and it may be
that inhibitors exert their effect by increasing this
potential. It has been noted that microscopy of
centrifuged, fresh whole urine, after evaporation,
reveals clusters of Calcium Oxalate crystals but that
this appearance is not seen if the urine is previously
subjected to ultrafiltration (pore size 12000 daltons)
(Hallson and Rose 1979). When uromucoid is returned to
the solution the cluster phenomenon is seen once more and
this is thought to be due to a high molecular weight
mucoprotein -the Tamm-Horsfall mucoprotein, triggering
the nucleation of crystals of Calcium Oxalate and Calcium
Phosphate on strands of insoluble polymerised uromucoid.
Experimental evidence suggests that the degree of
crystallization is also pH dependent, increasing with pH
(although this is partly in association with Calcium
Phosphate crystals). Further experimental evidence shows
that while increasing crystallization can be achieved by
increasing the concentration of either Calcium or Oxalate
in a study solution, Calcium levels have to be raised to
a concentration corresponding to severe hypercalciuria in
vivo to cause this effect. A much greater increase in
crystallisation is achieved by raising Oxalate levels to
a lesser extent, corresponding to a urinary Oxalate just
above the normal range, (Robertson 1968). This would
suggest that while both Calcium and Oxalate levels are
important, that perhaps Calcium Oxalate crystalluria is
more critically sensitive to changes in Oxalate
concentration. In view of earlier difficulties in the
assay of Oxalate the reported prevalence of significant
hyperoxaluria in stone formers varies from 2 - 3 % to as
much as 40 - 50 %, (Bailey 1974, Robertson 1980, Wallace
1981, Baggio 1983 and Pena 1987). Williams and Wandzilak
(1989) concluded that a figure of 10 -20% was more likely
which would agree with the figure of 17% reported by Bek
Jensen in 1989.
URATE
Urinary Uric Acid is derived from protein in the
diet or from purines produced by endogenous breakdown. In
either event purines are first dephosphorylated to form
Hypoxanthine which is oxidised to Xanthine and then to
Uric Acid, both oxidation reactions being controlled by
Xanthine Oxidase. The Urate so produced is passed from
the plasma to the kidney where it is secreted in the
urine.
It is well described that patients with abnormal
purine metabolism excrete increased amounts of uric acid
in the urine, often resulting in the formation of non -
calcified urate stones. Such patients characteristically
have acidic urine favouring the formation of relatively
insoluble uric acid.
Sodium Urate > Uric Acid
High pH pKa= 5.75 Low pH
The management of such stone formers is to encourage
a high urine output and to increase urinary pH to <6.5 in
order to promote formation of the more soluble ionised
urate ( pH values of >6.5 will cause crystallization of
calcium phosphate upon pre-existing Urate calculi.) An
additional treatment is the long term ingestion of
Allopurinol a drug which specifically inhibits Xanthine
Oxidase thus blocking uric acid production.
Much more controversial is the contention that
urinary Urate levels are raised in idiopathic Calcium
stone disease, and play an active part in mediating
Calcium Oxalate stone formation. Coe (1978) felt that
there was an association, as did Robertson in 1978,
reporting significant hyperuricosuria in Calcium Oxalate
stone formers. Hodgkinson (1976), Strauss et al (1982)
and Fellstrom (1982) however drew opposing conclusions.
Hallson and Rose (1982) found no effect of Urate on
Calcium Oxalate crystallisation in whole urine while Pak
(1979) and Ryall (1986) report otherwise. The confusion
may partly be explained by the difficulty in establishing
a normal reference range. Not only do "normal" values
vary geographically travelling West to East in Europe but
normal values in a defined population and region seem to
have increased over the last few decades. This trend may
simply reflect increasing affluence with Man's
predilection for animal protein and underlines the perils
awaiting the unwary epidemiologist who might be tempted
to compare geographically distinct study populations or
use historical controls.
Most Western European laboratories quote an upper
limit of normal Urate excretion as 4.7 mmol/24hr ,however
recent series suggest that levels up to 7 mmol/24hr are
not unusual.
Fleisch (1978) proposed that Calcium Oxalate
crystalluria might be promoted by the process of Epitaxy
whereby different substances whose crystal lattice
structures are of similar dimensions can mutually enhance
the crystallisation of the other. Pak (1979), on the
other hand, suggested that the inhibitor capacity of
Glycosamino-glycans (GAGs) in urine was reduced by
adsorption by Urate so enhancing Calcium Oxalate
crystallisation.
Despite the controversy surrounding the mechanism
involved, there is some clinical evidence to support a
role for Urate in idiopathic stone disease. In recent
controlled trials a reduction either in Oxalate excretion
or in episodes of stone recurrence is claimed in response
to treatment of idiopathic stone formers with Allopurinol
(Tomlinson 1985), (Scott 1978 and 1989). This is
theoretically possible since Xanthine Oxidase is one of
the endogenous enzymes capable of catalysing the
oxidation of Glyoxylate to Oxalate ; an inhibitor of
Xanthine Oxidase such as Allopurinol could therefore
reduce Oxalate synthesis and ultimately, urine Oxalate
levels. A recent publication by Urivetsky (1990) while
concurring with the observations of Scott and Tomlinson
et al in demonstrating a fall in both urinary Urate and
Oxalate after treatment with Allopurinol, showed in a
follow-up study that the difference could have resulted
from change in diet alone, and was not dependant on
Allopurinol. Raised levels of Oxalate excretion were
noted in individuals consuming a high protein diet and
vice versa whether on or off Allopurinol. While it is
accepted that Allopurinol will reduce Urate excretion in
hyperurocosuric Calcium Oxalate stone formers it remains
uncertain whether this reduces the rate of stone
recurrence. Finlayson (1985) and Hofbauer and Zechner
(1988) felt there was no evidence to support such a
claim. A recent report by Ettinger (1989) agreed that the
only examples of improvement in recurrence rates were
found where Allopurinol had been given selectively to
normo - Calciuric patients, and that no case had been
made for the use of Allopurinol in the treatment of stone
formers exhibiting both hypercalciuria and
hyperuricosuria. This is particularly relevant in view of
the reported increase in allergic reactions when Thiazide
and Allopurinol are used in combination.
INHIBITORS
As well as researching the positive factors relating
to crystalluria and stone formation considerable effort
has been exerted in order to establish the role of
negative factors or inhibitors. If such substances are
present and active at the physiological concentrations
found in the urine of normal individuals, their
deficiency or absence, observed in some stone formers may
be significant. Many urinary constituents have been
suggested as inhibitors i.e. protective colloids, (Butt
1952), small ions such as Citrate, (Howard and Becker
1976), Magnesium, (Muckai and Howard 1963),
Pyrophosphate, (Fleisch and Bizaz 1964), anionic
macromolecules, (Robertson 1973/1976) such as GAGs, RNA,
acidic glycoproteins and non-polymerised Tamm-Horsfall
mucoprotein.
Inhibitors are thought to act by adsorbing to the
surface of crystals slowing down the kinetics of growth
and agglomeration (Scurr and Robertson 1986) . Citrate as
well as acting in this way regarding Calcium Oxalate and
Calcium Phosphate crystals also reduces the risk of stone
formation by forming soluble complexes with Calcium(Ca++)
thus reducing the ionic concentration. Magnesium and
Sodium form similar complexes with Oxalate (Smith 1989).
Magnesium and Citrate therefore exhibit the dual effect
of inhibition and complexation (Nancollas 1976). There
have been many claims and counter claims based on
investigations and treatments arising from them.
MAGNESIUM
An early possible inhibitor to be considered was
Magnesium. Hammarsten (1929) noted that in simple
solution it formed soluble complexes with Oxalate and
reduced Calcium Oxalate crystalluria and these findings
were supported some years later by Fleisch (1978) and by
Hallson et al (1982). On the other hand, this view was
not supported by Sutor's experimental results in 1970.
Good results of treatment with Magnesium compounds have
been claimed by Melnick (1975) and Johannson (1980) and
most recently a mixture of Magnesium and Tartrate has
been advocated by Hallson and Rose (1988) which resulted
in an increased level of urinary Citrate and Magnesium
and a reduction in urinary Calcium.
MUCOPOLYSACCHARIDES
Another group of substances found in the urine and
proposed as having inhibitor properties are the
Mucopolysaccharides. Robertson et al reported in 1973
that such a substance inhibited the agglomeration of
Calcium Oxalate Monohydrate crystals in vitro, however,
subsequent reports have been unable to agree. Bowyer
(1979) nominated Chondroitin Sulphate as a possible
example and it has been claimed by some that the stone
promoting ability of Uric Acid relies on blocking the
inhibitor action of this group of substances. Fleisch in
1978 distinguished between "precipitation"
and"aggregation" stating that while for both Calcium
Oxalate and Calcium Phosphate stones the important
inhibitors of precipitation were Citrate and
Pyrophosphate, GAG's were important inhibitors of
aggregation. Sutor in 1979 in a set of "whole" v
"synthetic" urine experiments while agreeing with the
action of Citrate and Pyrophosphate could find no
evidence either of an occult, unidentified inhibitor nor
of any such effect with GAGs. At about the same time Pak
reported the results of his studies on two
macromolecules, namely Heparin and Chondroitin Sulphate,
the latter having been suggested the previous year as a
likely Inhibitor, (Bowyer 1979). According to Pak, the
marked inhibitor action of Heparin could be demonstrated
in test solutions, as evidenced by the rise in the
Formation Product of Calcium Oxalate which occurred when
Heparin was added to the solution, at a concentration of
0.05mg/litre. In addition, this effect could be blocked
by prior incubation of the mucopolysaccharide with
Monosodium Urate although this latter effect required a
Urate:Heparin ratio of 2000:1 which would be unlikely in
physiological conditions.
In 1981 Koide reported the results of his
experiments to assess the degree of inhibition of
aggregation found in the urine of stoneformers and
controls. The urine was first filtered to remove such low
molecular weight substances as Citrate and Pyrophosphate
and so isolate the effect of urinary macromolecules
(m.w.>10,000). He found a much greater inhibitory effect
in the non stone formers' urine which could be abolished
using a protease, suggesting that it was indeed a protein
complex, however, urinary acid GAG's were thought not to
be important inhibitors.
Ryall (1984) compared the inhibitory activity of
urine from stoneformers and Controls, specifically
looking at levels of GAGs, Urate and any mutual
interaction. While identifying degrees of inhibitory
activity, she could find no difference between
"unselected" Stoneformers and Controls, concurring with
Koide (1979) and Sallis (1979) that macromolecules other
than GAGs had a more important inhibitory role. In 1988,
Hwang and Preminger et al also reporting a large series
of quantitative urine analyses, could find no difference
between stoneformers and controls. Nikkila in 1989 found
that when recurrent stone formers were examined
separately from first time stone formers then a
significant reduction in GAG excretion compared with
controls could be demonstrated, supporting the
"selective" findings of Ryall.
The role of Macromolecules as Inhibitors thus
remains contentious; no attempt has been made to
establish further their relevance to Urolithiasis during
the course of this study.
PYROPHOSPHATE
Pyrophosphate has been claimed by some (see above)
to be an inhibitor of stone formation on the basis of in
vitro experimental work, however others feel that
sufficiently high concentration needed to be effective in
this capacity could not be achieved under physiological
conditions. Hallson and Rose (1983) concluded that
Pyrophosphate had no role to play in modifying Calcium
Oxalate or Phosphate crystal formation in whole urine. It
may be that any effect however small, is exerted by
adsorption on to crystal surfaces preventing aggregation
as suggested by Sutor in 1979.
CITRATE
Citrate is another normally occurring urinary
constituent which is said to have a role as a natural
inhibitor of stone formation and there are several ways
in which this effect might be achieved. Its excretion
reflects renal intracellular metabolism and acid-base
status (Simpson 1983) and varies with the acid content of
the diet (Gamble 1961). Renal acidification abnormalities
are not uncommonly associated with nephrolithiasis and in
such patients hypocitraturia is often a feature. (Backman
1961). Hastings showed in 1934 that Citrate formed
soluble complexes with Calcium reducing the urinary
saturation with Calcium salts and there is also evidence
that it may inhibit the growth and/or aggregation of
crystals of both Calcium Oxalate and Calcium Phosphate,
(Meyer 1975, Felix 1977, Ryall 1985, Kok 1986.) Hallson
and Rose noted that Citrate significantly reduced both
Calcium Oxalate and Calcium Phosphate crystal formation
in vitro using a rapid evaporation technique (1983).
There have been difficulties to overcome, however,
both in technique and interpretation especially regarding
the early reports. The method of assaying Citrate using
Bromacetone (Natelson 1948) proved to be somewhat
unsatisfactory therefore early reports on Citrate levels
are less reliable than later studies carried out after
the introduction of a specific enzymatic method of
estimating Citrate using Citrate Lyase. (Moellering 1966)
In addition, it has been shown that certain bacteria can
degrade Citrate, thus post renal destruction of Citrate
can occur, either in vivo in the presence of an UTI or
when completed urine collections become contaminated
before analysis, both circumstances resulting in
spuriously low Citrate levels. Conway et al (1949)
concluded that urine infection accounted for all cases of
hypocitraturia, however, Hodgkinson (1962) claimed that
low urinary Citrate excretion was more likely to reflect
impaired renal function. Certainly later studies have
shown a relationship between renal failure and low
urinary Citrate as a result of reduced filtered load.
Buckalew in 1989 showed that in patients with Renal
Tubular Acidosis (RTA), characterised by low urinary
Citrate, there was a linear relationship between plasma
Bicarbonate and Creatinine clearance (provided Creatinine
clearance was less than 80 mis / minute.)
Shorr et al (1942) showed a marked difference in
urinary Citrate levels between males and females as a
result of ovulatory oestrogen rises, pointing out that-if
groups of stoneformers were not stratified for sex before
analysis then serious errors could arise. In addition
Hosking (1985) reported a rise in Citrate excretion with
increasing age in both sexes in normal individuals which
was not seen in stone formers of either sex.
In 1976 Welshman and McGeown reported their results
taking account of all the above pitfalls and concluded
that while there was a significant difference in Citrate
excretion between (especially young) male and female
adult Controls, there was no significant difference
between Male and Female stoneformers. When compared with
controls, however, there was overall a degree of
hypocitraturia in stone formers which reflected neither
infection, poor renal function nor inadvertent sexual
bias. In addition they observed a significant linear
relationship between urinary Calcium and Citrate
excretion in all groups examined, but particularly marked
in young adult females (see Results of this study). In
1979 Schwille et al reported a significant reduction in
Citrate excretion in a group of recurrent Calcium Oxalate
stoneformers compared with Age and Sex matched Controls.
Nicar (1983) also demonstrated significantly low Citrate
levels in approx 50% of an unselected group of
stoneformers of differing aetiologies, except in Calcium
Oxalate stone formers who were also hyperuricosuric (see
results of this study). He also observed significant
correlation between Citrate and Calcium excretion
(p<0.025), surmising that divalent cations such as
Calcium and Magnesium might enhance Citrate excretion by
forming complexes with Citrate and thus preventing its
reabsorption. In the same year Menon and Mahle (1983)
reported significant hypocitraturia in 15% of a group of
Calcium Oxalate stone formers of whom 13% had no other
demonstrable abnormality. This was followed two years
later when Pak (1985) reported the results of treating a
group comprising only Calcium nephrolithiasis patients,
with Potassium Citrate. Not only was urinary saturation
with Calcium Oxalate reduced and the propensity for
spontaneous nucleation of Calcium Oxalate diminished (as
shown in vitro by experiments using the urine of treated
patients) but the rate of stone episode recurrence was
reduced in 80% of the treatment group. This latter aspect
of this study is open to criticism as there was no
non-treatment group and such apparent improvement may
easily arise simply as a result of a placebo or
"stone-clinic" effect.
In 1986, Kok reported a set of experiments using the
urine of controls and stoneformers, the only detectable
abnormality in the stoneformer group being
hypocitraturia. Using a seeded crystal growth system he
was able to assess separately, degrees of both inhibition
of crystallisation and aggregation. While both control
and patient urines were equally good at inhibiting
crystallisation, the stone-formers' urine was
significantly poorer at preventing aggregation,
suggesting that the Citrate was acting as an inhibitor of
crystal aggregation in the control group.
Regardless of its place in the aetiology of
idiopathic stone disease, the observation of low Citrate
levels in conditions associated with renal acidification
defects which themselves often accompany Nephrolithiasis,
is well described (Fourman and Robinson 1953, Backman
1980, Buckalew 1989). The commonest example is the distal
variant of type 1 Renal Tubular Acidosis although similar
defects in acidification have been reported in
association with Medullary Sponge Kidney (MSK) (Osther
1988). In type 1 RTA the major abnormality is the
inability to create a H+ ion gradient between tubular
cells and urine in the presence of acidaemia. If the
lesion is complete the clinical picture is one of
Hyperchloremic Acidosis, Hypercalciuria, High urinary pH,
Hypokalemia and Hypocitraturia. The urinary pH cannot be
reduced below 5.3 (Urine can be acidified to pH of 4.5 in
health) and fixed bases, Na+, K+ and Ca++ are lost in the
urine (Dedmon 1962) (Morrissey 1963) (Buckalew 1989).
The incomplete distal form of the condition is the
only significant variant which is relevant to
Nephrolithiasis. There is no overt acidosis, the
diagnosis relying on a challenge with an oral acid load
in order to prove the defect in urinary acidification
capacity. Incomplete distal RTA is infrequently reported
in the UK, possibly as it is seldom sought, however,
according to the literature it occurs in up to 20% of
presentations with renal stones in North America and
Scandinavia (Preminger 1985) (Backman 1980), although
whether it is the underlying cause, or arises from
secondary to renal pathology is less clear.
Buckalew (1989) classifies type 1 RTA as being
Hereditary, Idiopathic or Secondary, stating that
secondary forms are often associated with autoimmune
disorders and occur more frequently in female subjects.
This would be in keeping with the findings of Backman et
al (1980) who in a study of 318 recurrent stone formers
found impaired renal tubular function in 19 % of cases,
most of whom had incomplete type 1 RTA. This impaired
renal acidification occurred in 13 % of male stone
formers and in 38 % of female stone formers.
While it would be facile in this complex condition
to claim that all cases of Nephrolithiasis were due
solely to Hypocitraturia, it is noteworthy that Preminger
and Pak (1985) have reported excellent results from
treating RTA with the alkali Potassium Citrate orally,
demonstrating an objective reduction in urinary Calcium
excretion, an increase in urinary Citrate and a lowering
of the relative urinary saturation product of Calcium
Oxalate. The use of Sodium Citrate, while increasing
Citrate excretion, did not bring about a corresponding
reduction in urine Calcium concentration by virtue of the
increased Sodium load. It is relevant at this point to
mention a less desirable consequence of Thiazide
treatment in the management of idiopathic hypercalciuria.
The secondary hypokalemia results in hypocitraturia,
thereby possibly reducing one stone risk factor at the
expense of raising another. This complication can be
avoided by the use of Potassium supplements in
combination with Thiazides and clearly Potassium Citrate
would be an appropriate choice.
In summary therefore it appears that Citrate
complexes with Calcium and restricts Calcium Oxalate
stone formation by in this way as well as by disturbing
the process of crystallisation and/or aggregation,
although it may be that in some series reported in the
past that spuriously low levels of urinary Citrate in
fact resulted from urine infection, poor renal function
or failure to take note of sex differences.
It is to be hoped that in the clinical study that
forms the basis for this Thesis adequate notice has been
taken of the errors and pitfalls which beset earlier
workers and that this work will provide an accurate
reflection of the relevance of citrate excretion in
stoneformers from East Central Scotland.
RENAL CALCIFICATION
In the search for an underlying cause of renal
calculi, attention has been focused not only on the
composition of the urine but also on the renal substance
itself, which has come under scrutiny to try to gain a
clue as to the mechanism of stone production. To this
end, radiological and both light and electron microscope
studies have been carried out on normal as well as
stone-formers' kidneys. Commencing with Virchow's report
of calcified renal deposits which he described as 'Kalk
Metastasen' in 1855, the initial site of formation and
subsequent progress of microcalculi within the kidney has
been a subject of intense debate. In 1936 Randall
described the presence of macroscopic subepithelial
plaques of calcification situated on the papillae of 20%
of kidneys examined and this work was followed by the
microscopic studies of Anderson and McDonald (1946) where
some degree of calcification was demonstrable in all
patients examined (although this study of 168 patients
was confined to the renal medulla). Haggitt and Pitcock
(1971) conducted a pathological study of 100 kidneys
removed at autopsy. This study was also confined to
medullary examination and again no reference was made to
a history, or not, of previous nephrolithiasis. Varying
degrees of calcification, confined to the basement
membranes and interstitia of collecting ducts, was noted
in all cases, the Electron Microscope appearance being
dense laminated spherules which were very rarely located
within the Nephron. Malek and Boyce in 1973 published the
results of their studies in which the findings in
stoneformers and non-stoneformers were considered
separately. In a group of 64 patients with
nephrolithiasis of varying aetiology calcified deposits
were noticed within the proximal and distal tubular cells
as well as within the tubular lumina in 52/64 (81%) of
stoneformers overall, however this corresponded to 100%
of those patients with Calcium Oxalate lithiasis there
being no deposits in those with a history of Infective
(Struvite), Urate or Cystine stones. In this study there
appeared to be a gradient of microcalcification
increasing from the Cortex towards the Medulla which was
maximal at the papillary tip. In the Control group, in
the 29 who had no history of stone disease, only 3 (10%)
showed evidence of microcalcification. He postulated that
the initial event was the formation of a microcalculus
within the mitochondria of the renal tubular cells which
subsequently disrupted the organelle to occupy the
tubular cell. The tiny concretion resulting from
aggregation of several of these microcalculi might then
rupture into the tubular lumen of the parent nephron
whence it could migrate towards the medulla, passing via
the papillae into the urine or becoming occluded at the
level of the collecting ducts or in a subepithelial
distribution to form a Randall's plaque. This putative
sequence of events received a measure of support from
animal studies performed by Caulfield (1963) when renal
calcification was artificially produced by intra
peritoneal injections of either PTH or Calcium Gluconate
in mice. The animals were subjected to varying
frequencies and concentrations of the injections and were
sacrificed at intervals when E/M studies of the kidneys
were carried out. In this study the earliest appearance
of calcium deposition was within the mitochondria of
tubular cells, intraluminal calcification being seen
later. It is worthy of note however that the earliest
sacrifice was performed at 48 hrs after injection. In a
similar study by Khan et al (1979) intraperitoneal
injections of Sodium Oxalate were given to rats in order
to induce renal Calcium oxalate crystal formation. In
this latter study crystal formation was shown to be
primarily an intra-luminal phenomenon confined to the
proximal tubules of the Cortex with subsequent
progression distally towards the papilla. This finding
was demonstrated in animals sacrificed only 15 minutes
after injection; crystals were found in renal tubular
cells and within the interstitium only in animals
sacrificed at 7 days or longer after injection. That
interstitial Calcium deposits can arise secondary to
intraluminal Calculosis was previously asserted by
Roberts (1976) and Epstein (1971).
In a personal study (Harrison and Inglis, 1988)
renal biopsies were taken from stoneformers at the time
of PCN and compared with Controls. In our preliminary
study, Calcification was present in 72% of Stoneformers
but only 23% of Controls. The calcified deposit was
either a small amorphous body present within tubular
lumina, tubular cells, or rarely within the interstitium,
a much less common form being found in relation to the
basement membrane of Bowman's capsule. Electron
microscopy was carried out on 5 cases in which light
microscopy had demonstrated calcified deposits. There
were no Ultrastructural abnormalities but small electron
dense bodies were demonstrated within tubular cell
basement membranes and mitochondria which were larger and
more numerous than mitochondrial bodies observed in
Controls. In the Control patients with no history of
stone disease Calcium deposits were very much rarer and
were mostly confined to the collecting tubules within the
Medulla.
In conclusion therefore it would appear that there
is a reasonable consensus amongst the published evidence
over the last 50 years that while small deposits of
Calcium can be detected microscopically in kidneys of non
stoneforming individuals, most commonly in the region of
the renal papillae, the incidence and extent of such
calcification is increased dramatically in stoneformers,
particularly of Calcium Oxalate type. A possible sequence
of events comprising a cellular or biochemical
abnormality in the urine occurring within the lumen of a
cortical tubule or tubular cell, allowing formation of a
tiny concretion. This tiny calculus which either
primarily or secondarily reaches the lumen, subsequently
progresses distally to the papillae to be voided as
microcalculi in the urine. Their course however may
become impeded at various points along this route and if
such occurs they may form a nidus for further
aggregations of small concretions with subsequent
development of a renal calculus.
PATIENTS, MATERIALS and METHODS
In Edinburgh prior to the establishment of an
extra-corporeal Lithotripsy service, the majority of
Renal Calculi requiring active intervention were treated
by Percutaneous Nephrolithotomy (PCN). The operation of
PCN is carried out under G.A. usually as a single stage
procedure with antibiotic cover (Inglis 1988). The renal
collecting system is first imaged fluoroscopically by
injection of contrast via an ureteric catheter passed at
the time of preliminary cystoscopy. After turning the
patient prone the opacified system is punctured through
the most favourable calyx and after passing a guide wire
into the collecting system, graduated dilators are passed
serially until a track large enough to accommodate an
Amplatz tube is created. The nephroscope is passed along
this latter tube and using fibre optic illumination and
saline irrigation the stone can be visualised and either
removed intact or piecemeal, following preliminary
fragmentation using an Ultrasound or Electro-hydraulic
probe.
At the end of the procedure and before insertion of
a nephrostomy tube for drainage, endoscopic biopsies of
the renal parenchyma were taken using standard cup-biopsy
forceps at a site distant from the location of the stone
and from tissue which was of normal appearance.
The nephrostomy tube was removed when the urine drainage
was clear and the patient discharged home 24 hours later.
Further assessment of urinary parameters was undertaken
as ambulatory outpatients.
Renal Biopsies
Renal biopsies were performed in 69 stoneformers
overall (48 Male and 21 Female) however a number of
patients were lost to follow up or failed to complete
subsequent urine collections, therefore comparative Data
on Biopsies and Urine chemistry is available on 47
patients. The biopsies were examined using light
microscopy to seek evidence of renal parenchymal micro-
calcification, any associated pathology and their
relevance to urine biochemical abnormalities and
Nephrolithiasis. In addition some sections showing
evidence of Calcification on light microscopy were also
examined by Electron Microscopy. The histo pathological
assessment was conducted throughout by a single
pathologist ( D. H.)
The biopsies were initially fixed in 10% buffered
formalin and embedded in paraffin wax. Calcium was
demonstrated using two techniques; the first, using von
Kossa silver, substitutes a dark brown silver deposit for
carbonate or phosphate, and while not specific for
Calcium is regarded as valid (Pearse 1972). The second
complementary method uses Alizarin Red which at a pH of
4.2 dissolves Calcium deposits to form red calcium lakes
(Pearse 1972) . Control renal tissue was also examined for
comparison of the relative amount and site of
calcification compared with stoneformers. This material
was obtained from 30 renal biopsies (either open-wedge or
needle) carried out on patients suffering from any of a
number of mixed renal pathologies excluding nephro¬
lithiasis i.e. ATN, Hypertension and Glomerulo-
nephropathy. In addition two kidneys obtained at necropsy
and one removed surgically for tumour were assessed by
multiple biopsies to confirm that a single cup biopsy was
representative of the kidney as a whole.
Urine and Blood Analyses in Stoneformers
The patients included in the above study were 87
consecutive adult idiopathic stone formers attending RIE
for PCN. The group who were all resident in East Central
Scotland comprised 58 Males and 29 Females. They all had
radiographic evidence of Calcium nephrolithiasis, were
unselected regarding stone size and were otherwise in
good health with normal renal function. They were,
however, excluded from the study if there was any past or
present history of urinary infection. Any patient found
at preoperative screen to be Hypercalcaemic was referred
for appropriate investigation of the cause and excluded
from this study of idiopathic stone formation.
This group of patients had had no specific dietary
advice regarding stone prophylaxis and were on no
medication thought to affect stone precursor metabolism
i.e. Thiazides, Cellulose Phosphate etc.
At the time of Out-Patient review a series of
additional biochemical investigations was arranged and
supervised personally. These included estimation of serum
Calcium, Urate and Urea and/or Creatinine (to confirm
normal renal function) as well as Arterial blood gas
analysis. 24 hour urine collections were completed in
containers to which 50ml of 5M HC1 had been added to
prevent any bacterial degradation of Citrate in vitro and
also prevent any conversion of Ascorbate to Oxalate. All
collections were returned to me so that the volume could
be measured and recorded. Two 20 ml aliquots were deep
frozen for subsequent Oxalate and Citrate assay, the
estimation of Calcium, Urate and Creatinine being
performed locally in the Biochemistry Dept.of the Royal
Infirmary of Edinburgh.
Under the supervision of Professor L.G. Whitby,
serum Calcium and Urate as well as urinary Urate was
analysed using a Technicon Simultaneous Multiple Analyser
with Computer II (SMAC II) system and urinary Calcium
measured on a Technicon RA - 1000 Random Access Analyser
(Technicon Instruments Co., Basingstoke, Hants.)
Arterial blood gas specimens were drawn solely by
myself using disposable pre-heparinised vacuum syringes
from radial artery punctures after infiltration with 2%
Lignocaine. The samples were delivered to the laboratory
personally, on ice, within 30 minutes of sampling and
analysed using an IL 1312 automatic blood gas analyser
(Instrumentation Laboratories, Warrington, Lancashire).
It was not possible for this laboratory to perform
assays for urinary Citrate or Oxalate. Thanks to the
generous cooperation of Mr Ian Gibb, Principal Biochemist
at the Freeman Hospital, Newcastle on Tyne and
Dr.G.A.Rose and his team, at St.Pauls Hospital/Institute
of Urology in London, the estimation, respectively, of
these latter two parameters was carried out for both
study group and control urines.
Controls.
Rather than rely on historical Controls it was felt
preferable to duplicate all urine collections and
analyses exactly, in a group of contemporary Control
subjects, in the same laboratory. Clearly it would have
been inappropriate for ethical reasons to perform
invasive procedures such as renal biopsy and arterial
puncture on control subjects; the source of control renal
tissue has been referred to above. Normal blood gas
parameters were obtained from the laboratory undertaking
the analyses.
44 adults attending the Outpatient Dept. for reasons
other than Nephrolithiasis, with no history or clinical
evidence of Urinary infection or Renal impairment were
asked to complete 24 hour urine collections as above. On
receipt of a negative MSU result, the urine was analysed
for Calcium, Urate, Oxalate, Citrate and Creatinine after
stratification for age and sex.
Urinary Citrate Estimation.
Citric Acid is converted to Oxalo acetate and
Acetate in a reaction catalysed by the enzyme Citrate
Lyase (CL)
(i) Citrate > Oxaloacetate
CL
In the presence of the enzymes Malate Dehydrogenase (MDH)
and L- Lactate Dehydrogenase (L-LDH), Oxaloacetate and
its decarboxylation product, Pyruvate are reduced,
respectively, to L-Malate and L-Lactate by reduced
nicotinamide-adenine dinucleotide (NADH).
(ii) Oxaloacetate + NADH + H+ > L-Malate + NAD+
MDH
(iii) Pyruvate + NADH + H+ > L-Lactate + NAD+
L-LDH
The amount of LDH oxidised in reactions (ii) and
(iii) is stoichiometric with the amount of Citrate. NADH
is determined by means of absorbance at 340 nm using the
kit manufactured by Boehringer Mannheim GmBH (Cat No.
139076) Analysis was carried out on COBAS BIO centrifugal
analyser (manufactured by Roche Products Ltd.)
Sensitivity of the method
The minimum concentration of Citrate measurable with
95% confidence was 0.2 mmol/L.
Urinary Oxalate Estimation
The main reactions that occur with Oxalate are
a) Oxidation to H20 and C02 or
b) Reduction to Glycollate via Glyoxylate
H0-C=0








Previously fashionable methods can be divided into
those requiring separation of the Oxalate from other
potentially interfering substances such as Citrate,
Magnesium, Ascorbate and Glyoxylate and those using whole
urine. In the former group, such preliminary steps
included Precipitation, Solvent extraction and Ion
exchange chromatography which themselves were complicated
by problems of incomplete separation due to
contamination, the presence of Inhibitors and lack of
specificity.
The subsequent development of methods using whole





The chemical method using KMn04 as an oxidising
agent underestimates Oxalate, is not specific and has a
low sensitivity. Physical methods using Gas or Ion
Chromatography have encountered difficulty with the in
vitro conversion of Ascorbic acid to Oxalate during the
assay. Enzymatic methods have proved most satisfactory in
view of their inherent specificity for Oxalate and
because no preliminary separation from urine matrix is
required.
Two different enzyme methods have been developed
i) Oxalate decarboxylase (Hallson and Rose, 1974)
ii) Oxalate oxidase (Kasidas and Rose, 1985)
+ 02 COOH -C02
C02 + H202 < >HCOOH Formate
COOH
Oxalate oxidase Oxalate decarboxylase
The earlier method, was effective but labour
intensive, requiring overnight incubation and was not
suitable for automation. The advantages of the Oxalate
oxidase method include, the use of whole urine, a highly
specific and sensitive assay (0.5u mol/L), automation,
cost effectiveness (enzyme reusable) and lack of
ascorbate interference.
SUMMARY OF RESULTS
Statistical analysis of results was performed using
the "OXSTAT" statistical computer software package. Since
the groups being examined were unmatched, analyses were
performed by the Unpaired t-Test, where data were assumed
to be parametric. In cases of doubt regarding this latter
assumption, a non-parametric test, the Mann Whitney U
test was employed in addition, provided the groups were
numerically large enough. Suspected correlation between
unrelated groups was calculated and plotted graphically
using the above program and "r" values so obtained
matched with standard tables of statistics to assess
their significance.
Legend
Abbreviated symbols referring to various patient
groups are used throughout the Results section as follows
Male = 1 Female = 2 Control group = K
Calcium = Ca, Urate = Ur, Oxalate = Ox, Citrate = Ct,
Creatinine = Cr
e.g. 24hr Calcium excretion, Male stoneformers V Controls
24 Ca 1 | 24 Ca 1 K
Before analysing any of the data, Study subjects and
Controls were stratified for Sex, Age and Body mass,
(24hr Urinary Creatinine being used as an approximate
estimate of body mass, given normal renal function.)
Renal function was assumed to be grossly normal in the




Age (Years) Mean S.D.
Males 50.48 S.D. 11.92
Controls 51.20 S.D. 13.73
Females 49.34 S.D. 15.48
Controls 44.17 S.D. 17 .22
(81 - 2)
There was no significant difference between Males
and Controls or Females and Controls. Where the apparent
slight difference in Age between Females and Controls
might be thought to affect results, a more critical
breakdown of age pattern was undertaken. (See Citrate
analysis and Discussion)
Body masa ( Urinary Creatinine m mol/24hr )
Males 13.559 S.D. 4.437
Controls 11.632 S.D. 3.638
Females 9.192 S.D. 2.856
Controls 9.491 S.D. 1.941
(86-7)
There was no significant difference between Males
and Controls or Females and Controls.
As well as calculating 24hr excretion of a given
substance (S), in order to avoid any error as a result of
inherent 'body mass effect', the ratio (S)/Creatinine was
also calculated.
Renal Function Mean S.D. N
Serum Urea (males) 5.418 1.399 54
(females) 5.181 1.487 26
( Normal lab. values 2. 5 - 6. 6 m mol/L )
Serum Creatinine (males) 103.375 16.122 32
(females) 82.000 13.260 13
( Normal Lab. values 55 - 150 u mol/L ) ( 83 )
Serum Calcium
(males) 2.344 0.105 54
(females) 2.398 0.118 24
( Normal Lab. values 2.12 - 2.62 m mol/L )
Serum Urate
(males) 0.347 0.089 50
(females) 0.347 0.075 23
( Normal Lab values mmol/L) 0.12 - 0.36 Females
0.12 - 0.42 Males
(83 )
24Hr Urine Volume (L)
Males 2.02
Controls 1.45
S . D. 0.65
S.D. 0.57 p < 0.001
Females 1.80 S.D. 0.81
Controls 1.43 S.D. 0.60 p = 0.08
(84-5)
The difference between Males and Controls was
significant, however, the significance of this finding is
less certain. It may simply reflect the compliance with
medical advice to increase fluid intake.
Renal Biopsy - Microcalcification
Males Microcalcification present 28/48 = 58.3%
Females Microcalcification present 13/21 = 61.9%
Controls Microcalcification present 7/30 = 23.3%
The biopsies included on average 18 glomeruli
(Range 2-50)
Calcium was seen in approx. 60% of cases (Male = Female)
the majority occurring in the Medulla.
Renal Biopsy - Pathological abnormalities
In addition to calcification, a number of other
abnormalities was shown on biopsy |- Chronic Interstitial
Nephritis (an increase in interstitial cells by
subjective assessment), Fibrosis shown by MSB
preparations, Tubular Atrophy and Glomerular
Hyalinisation indicating permanent renal damage and a few
examples of Acute Tubular Necrosis and Mesangial
Proliferation.
Overall there appeared to be an association between
the presence of Calcification and other Pathology,
Calcium being present in 70% of cases where a
pathological abnormality was seen and in 35% of those
where histology was normal.
Examination of the Data on Renal biopsy
Calcification compared with Urinary excretion of Calcium,
Urate, and Oxalate showed no significant difference
between those with and without Calcium on biopsy. Similar
data relating Citrate excretion to biopsy appearance
shows a statistically significant difference in Males
(p = 0.014) paradoxically the group with Calcification on
biopsy having the higher Citrate excretion. Conversely,
in Females, while the Mean Citrate excretion is lower in
the group with microcalcification, this does not reach
statistical significance (p = 0.18), perhaps reflecting
the very small size of this subdivided group.
( 88 - 91 )
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RENAL BIOPSIES IN STONEFORMERS
Photographic prints by kind permission of Dr.D.J.Harrison
Dept. of Pathology, University of Edinburgh
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Acute Tubular Necrosis showing
Congestion and Tubulorrhexis
( H & E )
Renal Biopsy
NEGATIVE for Calcium













Microcalcification in Basement Membrane
Medullary Tubule ( von Kossa )
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Microcalcification in Bowman's Capsule
of Glomerulus ( von Kossa )
Legend: Calcification ( arrowed )
RENAL BIOPSIES - ELECTRON MICROGRAPHS
66
i) CALCIUM DEPOSITS IN TUBULAR BASEMENT MEMBRANES
ii) CALCIUM DEPOSITS WITHIN MITOCHONDRIA
RELATIONSHIP OF CALCIFICATION AND RENAL BIOPSY SITE
IN STONEFORMERS
TISSUE: CORTICO/MEDULLARY JNCT. MEDULLA CALYX
MALES (48)
Calcification + + +
Number of Cases 16 14 10 1 25
FEMALES (21)
Calcification + - + - + -
Number of Cases 8412 42
INCIDENCE OF CALCIFICATION AT 24/42 57.1%
CORTICO/MEDULLARY JUNCTION
INCIDENCE OF CALCIFICATION AT 11/14 78.6%
MEDULLA
INCIDENCE OF CALCIFICATION IN 28/48 58.3%
RENAL BIOPSY (MALES)
INCIDENCE OF CALCIFICATION IN
RENAL BIOPSY (FEMALES)
13/21 61.9%
RELATIONSHIP BETWEEN PATHOLOGICAL ABNORMALITY AND
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Urinary Calcium Excretion ( m mol / 24hr )
Males 8.131 S.D. 3.304
Controls 4.784 S.D. 2.827 p < 0.001
Calcium / Creatinine ratio p < 0.001
(92 - 4 )
The frequency distribution seems Gaussian for
standard Data however the data referring to Ca/Cr ratios
are positively skewed. Both para- and non-parametric
testing show highly significant differences between
groups. In 20% of Male stoneformers urinary Ca was
greater than Mean (Control) + 2 S.D.
Females 5.916 S.D. 3.422
Controls 2.855 S.D. 1.560 p < 0.001
Calcium/Cr Ratio p < 0.005
The frequency distribution was non-Gaussian. Both
para- and non-parametric tests show highly significant
differences between groups. In 39% of Female stoneformers
Urinary Calcium was greater than Mean Control) + 2 S.D.
( 95 - 7 )
Urinary Urate Excretion ( m mol / 24hr )
Males 4.539 S.D. 1.499
Controls 2.712 S.D. 1.429 p < 0.001
Urate / Cr Ratio p < 0.01
Stoneformers and Controls had a Gaussian
distribution. The reduced significance of Urate/Cr ratio
may reflect an underlying Mass effect. In 19.6% of Male
stoneformers urinary Urate was greater than Mean
(Control) + 2 S.D.
Females 3.404 S.D. 1.305
Controls 3.428 S.D. 1.494 p > 0.95
Urate/Cr ratio p = 0.508
There was no significant difference in Urate
excretion between Female stoneformers and Controls.
( 98-103 )
Urinary Citrate Excretion ( m mol / 24hr ) (110-14)
Males 2.384 S.D. 1.332
Controls 2.459 S.D. 1.663 p > 0.8
Citrate / Cr Ratio p > 0.6
There was no significant difference in the groups
using either parametric or non-parametric methods, the
frequency distribution in both Male stoneformers and
Controls showing a non-Gaussian pattern with a slight
positive skew.
Females 2.565 S.D. 2.054
Controls 4.078 S.D. 2.689 p = 0.056
Citrate / Cr. ratio p = 0.027
There is a significant difference between Female
stoneformers and Controls. The frequency distribution
however shows a non-Gaussian picture there being a skew
to the Left in both stoneformers and Controls. There is
also a suggestion that this group comprises two separate
populations.
Plotting this Data, (Female Citrate/Cr.Ratio v
Controls), reflects this skewed distribution and shows
that no stoneformers in fact fall out of the range
(Control Mean - 2 S.D.) ( 127 )
Citrate Excretion (Citrate/Cr Ratio) ( 116 )
Male Controls 0.206 S.D. 0.113
Female Controls 0.440 S.D. 0.278 p < 0.001
The Control values in Female subjects are
significantly higher than in Males, as has been shown in
other studies reflecting a presumed Oestrogen effect in
pre-menopausal women. As the female stoneformers in this
study form a marginally older population than the female
Control group, it could be argued that the difference in
observed Citrate excretion in this group reflects age
related hormonal effects rather than any other cause. To
investigate this possibility, further stratification of
stoneformer and Control groups by Age, into pre- and
postmenopausal sub-groups ( <50 yrs and > 50 yrs.) was
undertaken. It can be seen that the previously noted
difference between female stoneformers and controls is
preserved and therefore cannot be an Age related
phenomenon.
Citrate Excretion ( Female Stoneformers ) ( 129 )
^ 50yrs 2.79 S.D. 1.80
< 50 yrs 2.36 S.D. 2.33 p = 0.65
Citrate Excretion ( Female Controls )
> 50 yrs 4.25 S.D. 2.20
< 50 yrs 3.96 S.D. 3.07 p = 0.80
Exploring the hypothesis suggested by the frequency
distribution histogram for Citrate excretion in female
stoneformers that there were 2 separate populations
within the stoneforming group, the Data for Citrate
excretion were re-examined after exclusion of patients
(and Controls) with abnormal excretion of Calcium or
Urate or Oxalate. "Normal" was defined as within the
range, ( Control Mean + 2 S.D. ) .
Revised Citrate Excretion ( Excluding patients with
Calcium, Urate or Oxalate > Control Mean + 2 S.D. )
Males 2.374 S.D. 1.342
Controls 2.281 S.D. 1.587 p = 0.669
Citrate/Cr ratio p = 0.318
Revised Citrate Excretion ( Excluding patients with





S.D. 2.625 p = 0.002
p = 0.004
By excluding patients with high levels of Calcium,
Urate or Oxalate the difference between Stoneformers and
Controls becomes much more significant
(123 - 6 )
Urinary Oxalate Excretion ( m mol / 24hr )
Males 0.213
Controls 0.228
Oxalate / Cr Ratio
S.D. 0.117




Oxalate / Cr ratio
S.D. 0.084
S.D. 0.134 p = 0.412
p = 0.295
There was no detectable difference in Oxalate
excretion between stoneformers and Controls of either
sex. ( 104 - |09 )
STONE FORMATION INDEX
An attempt was made to devise a numerical index of
Lithogenicity based on various products of the excretion
Data presented above. No index, however, proved any
better a discriminant between Stoneformers and Controls
than the Calcium/Creatinine ratio alone.
The product Calcium x Urate which might be expected to
Citrate x Creatinine
exaggerate any difference between stoneformers and
Controls, showed the same significance as simple urine
Calcium/Cr ratios alone.
Male Stoneformers v Controls p < 0.001
Female Stoneformers v Controls p = 0.004
(130 -4 )
Coefficient of Correlation
There was no significant correlation between 24hr
Calcium excretion and 24 hr Creatinine excretion in Male
or Female Stoneformers although there was some positive
correlation in Male Controls (p = 0.015).
<135-6 )
There was no correlation between Urate excretion and
Creatinine excretion in Males however in Females there
was significant correlation. ( Stoneformers p = 0.069 and
Controls p < 0.001 )
As there was no observed difference between Female
subject and Control Urate excretion this was considered
insignificant. (137 39)
Citrate excretion in Male stoneformers was not
correlated with Creatinine excretion, however, in Females
there was a significant correlation (p = 0.003). As there
was no difference in Creatinine excretion between Female
stoneformers and Controls, this should not affect any
conclusions drawn regarding Citrate excretion in Females.
( 140-2 )
There was no correlation between Calcium and Urate
excretion in Controls, however, in both Male (p = 0.011)
and Female (p < 0.001) stoneformers there was an
association which was significant (and which persisted
when Urate/Cr and Calcium/Cr ratios were plotted,
(p < 0.001, p = 0.034)
This suggests that the observed difference in
excretion of Calcium and Urate in stoneformers compared
with Controls may not be independent variables.
(143-7 )
There was no correlation between Calcium and Citrate
excretion in Male stoneformers and the correlation
observed in Male Controls was no longer significant when
Creatinine ratios were examined.
In Female stoneformers significant correlation was
demonstrated (p < 0.001) and was only slightly reduced in
significance when Citrate/Cr ratios were calculated,
(p = 0.007). This finding could suggest a possibly
protective increase in Citrate with increasing
hypercalciuria in Female stoneformers. Another
explanation might be that Calcium and Citrate were
complexed together in the urine as suggested by Menon
(1983) who observed the same association.
In order to test the hypothesis that stone formers
with low Citrate excretion might have incomplete distal
RTA as an underlying cause, arterial blood gas analysis
was undertaken on all consenting stoneformers (but not in
Controls) in order to detect any degree of Metabolic
acidosis which might be present. Arterial Bicarbonate in
the stoneformer group as a whole was not outside the
laboratory reference range.
(148-52 )
There was no correlation between Citrate and Urate
excretion. ( 15:3 - 56 )
art. HC03 Male 23.08 S.D. 1.82
Female 24.08 S.D. 1.82
( ref. range 21 - 27.5 m mol / L )
157
When Coefficient of Correlation was examined
combining Data on arterial HC03 and Citrate/Creatinine
ratios, while there was no correlation found in Male
stoneformers, there was a positive correlation in Female
stoneformers which was significant (p = 0.031). This
observed association of low arterial Bicarbonate and low
Citrate Excretion in Females is consistent with a degree
underlying Renal Tubular Acidosis in a proportion of this
group of Stoneformers. ( J 61 - 64 )
Plotting of individual data points, however, (Female
Citrate/Creatinine | Controls) shows no stoneformers
outwith the range of Control values (Mean - 2 S.D.) as a
result of the positively skewed distribution.
( 127 )
In an attempt to clarify this finding, data
referring to Citrate excretion in Females (for both
Stoneformers and Controls) was recalculated after
deletion of all values of Citrate/Cr <0.16. in case the
group of samples with apparently very low Citrate
excretion had been contaminated after collection or
infected in vivo and were therefore spuriously low. In
total, 8/21 (38%) of female stoneformer group and 4/20
(20%) of Controls were thus deleted.
Subsequent parametric testing of remaining Data showed a
persisting significant difference between the groups,
(p = 0.06). There were insufficient remaining Data to
perform the non-parametric Mann Whitney U test.
When the reduced data on Citrate/Cr Ratios (Having
removed low Citrate values ?? RTA Patients) was once more
correlated with arterial HC03 data the previously
observed significant association was absent. This would
suggest that the low Citrate excretion group which was
deleted also included the slightly acidotic individuals
revealed by Arterial gas analysis and that this group
indeed have a degree of hypocitraturic acidosis (?RTA)
and have not simply been subject to sample contamination
or infection. (1)7—8, 165)
We showed (above) that Data comparing Citrate
excretion in Female stoneformers with Controls were more
significantly different after excluding patients with
abnormally high excretion of Calcium, Urate or Oxalate.
When these revised Data are correlated with Arterial
HC03 again a positive correlation is shown, r = 0.654
however the group size is small (N = 8), and statistical
significance is marginal, (p = 0.079).
Similar calculations in all the above groups
comparing H+ instead of HC03 shows no correlation: this
would be consistent with a degree of chronic compensated
acidosis rather than an acute phenomenon.
(158-60)
Correlation of Citrate/Creatinine ratios with Serum
Creatinine data ( equiv. to Renal Function) shows the
expected negative correlation of Urinary Citrate with
impaired renal function in female stoneformers (p = 0.05)
but this is not evident in Males. ( 170—73 )
As our study population had renal function within
the normal reference range this observation should not
affect our conclusions regarding Citrate Excretion and in
particular does not necessarily mean that Citrate
excretion in female stoneformers is low secondary to
impaired renal function. In fact serum Creatinine was
higher, overall, in male stoneformers yet no such
negative correlation between Citrate excretion and serum
Creatinine was observed.
( 169 )
COMPREHENSIVE DATA AND STATISTICAL ANALYSIS OF RESULTS





Set Name Mean SD SEM N
2 AGE 1 50.48 11.92 1.57 58
3 AGE 1 K 51.20 13.73 3.07 20
F ratio - 1.3259 fl - 19 £2 - 57 p >—o.:
Assuming Equal Variance : T - 0.2231 DF - 76 P
Assuming Unequal Variance : T - 0.2082 DF - 30 P
Unpaired T-Test
Set Name Mean SD SEM N
4 AGE 2 49.34 15.48 2.87 29
5 AGE 2 K 44.17 17.22 3.51 24
F ratio - 1.2368 fl - 23 £2 - 28 p >—0.!
Assuming Equal Variance : T - 1.1522 DF - 51 p
Assuming Unequal Variance : T - 1.1405 DF - 47 p
AGE DETAILS (FREQUENCY DISTRIBUTIONS)
Data from columns 2 to 2 and rows 1 to 134
X"Class dimensions YHhabari in olassas
20-
f , + 1 y 1 + 1 y 1
0.00 20.00 40.00 60.00 80.00 100
males
Data from columns 3 to 3 and rows 1 to 134
X^lass dimensions Y"Numbers in olassas
10-
Data from ooluans 4 to 4 and rows 1 to 134





0| ► 1 4- 1 V 1 + | V 1
0.00 20.00 40.00 60.00 80.00 100
females










0| v 1 + 1 y 1 + 1 f 1
0.00 20.00 40.00 60.00 80.00 100
* **
***
01 f 1 + 1 + 1 + 1 —+—I
0.00 20.00 40.00 80.00 80.00 100
male controls female controls
SERUM CALCIUM, URATE, UREA AND CREATININE (MMOLS/L) (MALE & FEMALE STONE FORMERS)
Calculations by Column:Including
Column Name Mean
4 SE. CA 2.3437







4 SE. CA 2.3988
Rows 1-29 FEMALES
S.D. S.E.M. Coef.V N













S.D. S.E.M. Coef.V N
0.0752 0.0157 21.6808 23
Calculations by Column:Including
Column Name Mean
6 SE. UREA 5.4185
Rows 56 - 113 MALES
S.D. S.E.M. Coef.V N
1.3991 0.1904 25.8201 54
Calculations by Column:Including
Column Name Mean
6 SE. UREA 5.1808
Rows 1-29 FEMALES
S.D. S.E.M. Coef.V N





















8 24VOL 1 2.0189
9 24V 1 K 1.4535
F ratio - 1.2894 fl
Assuming Equal Variance :




46 f2 - 19 p >—0.1
T - 3.3903 DF - 65 p - 0.001
T - 3.5703 DF - 41 p <0.001
Mann Whitney U Test.
Data from Column 8 and 9 including Row 1 to 134
Data set 1 24VOL 1 N - 47
Data set 2 24V IK N - 20
U - 239
Z - -3.1664 p - 0.002
Unpaired T-Test
Set Name Mean SD SEM N
10 24VOL 2 1.8033 0.8106 0.1769 21
11 24V 2 K 1.4258 0.6030 0.1231 24
F ratio = 1.8074 fl - 20 f2 - 23 p >-0.05 S p <0.1
Assuming Equal Variance : T - 1.7867 DF - 43 p - 0.081
Assuming Unequal Variance : T - 1.7519 DF - 37 p - 0.088
Mann Whitney U Test.
Data from Column 10
Data set 1 24VOL 2







Row 1 to 134
FREQUENCY DISTRIBUTION - 24 HR URINE VOLUME (L)
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Data from columna 8 to 8 and rowa 1 to 134
X-Cl&as dimanaiona Y™Numbara in
claaaaa
15-






01 ► 1—+ 1 ► 1 + 1
0.00 1.00 2.00 3.00 4
MALES
01 h I * 1 K 1 + I
0.00 1.00 2.00 3.00 4
FEMALES
Data from columna 9 to 9 and rowa 1 to 134
X*"Claaa dimanaiona Y—Numbara in
olaa
10-









01 + 1 4 1—f 1
0.00 1.00 2.00 3.00
MALE CONTROLS
oo i!oo s'.oo o'.oo 4
FEMALE CONTROLS




12 24CR 1 13.5587
13 24CR 1 K 11.6315
F ratio - 1.4877 fl
Assuming Equal Variance :










46 f2 - 19 p >-0.1
T - 1.7110 DF - 65 p - 0.092
T - 1.8541 DF - 43 p - 0.071
Mann Whitney U Test.
Data from Column 12 and 13 including
Data set 1 24CR 1 N - 47
Data set 2 24CR IK N - 20
0 - 363
Z - -1.4664 p - 0.142
Row 1 to 134
Unpaired T-Test
Set Name Mean
14 24CR 2 9.1919
15 24CR 2 K 9.4908
F ratio - 2.1637 fl
Assuming Equal Variance :




20 f2 - 23
T - 0.4151 DF -




p >-0.01 & p <0.05
43 p - 0.680
35 p — 0.688
Mann Whitney 0 Test.
Data from Column 14 and 15 including
Data set 1 24CR 2 N - 21
Data set 2 24CR 2 K N - 24
U - 228
Z - -0.5461 p - 0.584
Row 1 to 134
FREQUENCY DISTRIBUTION 24 HR CREATININE (MMOLS)
Data from columns 12 to 12 and rows 1 to 134
X*Class dimensions Y"Numbers in olassas
15-
Data from columns 14 to 14 and rows 1 to 134
X"Class dimsnsions Y"Numbers in classas
10-
oi—y—i—+—i—h—i—H—i





01 h I + 1 h 1 + 1
0.00 6.68 13.36 20.04 26.72
FEMALES
Data from columns 13 to 13 and rows 1 to 134
X^lass dimensions Y"Numbers in classes
10-
Deta from oolumns 15 to 15 and rows 1 to 134





0| +— y 1 |
0.00 6.30 12.60 18.00 25.20
MALE CONTROLS
►—|—+ 1—+ 1 + 1
00 <.60 13.36 20.04 26.3
FEMALE CONTROLS




Set Name Mean SD SEM N
1 CA+ 1 CA









10 f2 - 21 p >-0.01 & p <0.05
T -
T -
0.2144 DF 31 p
0.1811 DF - 14 p
0.832
0.859
Mann Whitney U Test.
Data from Column 1 and 5 including Row 1 to 134
Data set 1 CA+ 1 CA N - 22
Data set 2 CA- 1 CA N - 11
U - 8
Z - -0.1146 p - 0.906
Unpaired T-Test
Set Name Mean SD SEM N
9 CA+ 2 CA 5.46 2.48 0.88 8
13 CA- 2 CA 6.95 3.63 1.48 6
F ratio - 2.1451 fl - 5 f2 - 7 p >-0.1
Assuming Equal Variance : T - 0.9142 DF - 12 p - 0.379
Assuming Unequal Variance : T - 0.8638 DF - 8 p — 0.413
Mann Whitney U Test.
Data from Column 9 and 13 including Row 1 to 134
Data set 1 CA+ 2 CA N - 8
Data set 2 CA- 2 CA N - 6
U - 16




Set Name Mean SD SEM N
2 CA+ 1 UR 4.11 1.15 0.24 22
6 CA- 1 UR 4.16 1.79 0.57 10
F ratio = 2.4371 fl = 9 f2 - 21 p >-0.01 & p <0.05
Assuming Equal Variance : T = 0.0955 DF - 30 p - 0.925
Assuming Unequal Variance : T — 0.0811 DF — 12 p — 0.937
Mann Whitney U Test.
Data from Column 2 and 6 including Row 1 to 134
Data set 1 CA+ 1 OR N - 22
Data set 2 CA- 1 UR N - 10
U - 101
Z - -0.3661 p - 0.713
Unpaired T-Test
Set Name Mean SD SEM N
10 CA+ 2 UR 3.31 0.72 0.25 8
14 CA- 2 UR 3.28 0.87 0.43 4
F ratio - 1.4613 fl - 3 f2 - 7 p >—0.
Assuming Equal Variance : T - 0.0802 DF - 10 p
Assuming Unequal Variance : T - 0.0748 DF - 5 P
Mann Whitney U Test.
Data from Column 10 and 14 including Row 1 to 134
Data set 1 CA+ 2 UR N - 8
Data set 2 CA- 2 UR N - 4
U = 16




Set Name Mean SD SEM N
4 CA+ 1 OX 0.20 0.09 0.02 21
8 CA- 1 OX 0.19 0.08 0.03 9
F ratio = 1.4602 fl - 20 f2 - 8 p >=0.1
Assuming Equal Variance : T — 0.1775 DF = 28 p = 0.860
Assuming Unequal Variance : T = 0.1917 DF • 18 p ■ 0.850
Mann Whitney O Test.
Data from Column 4 and 8 including Row 1 to 134
Data set 1 CA+ 1 OX N = 21
Data set 2 CA- 1 OX N = 9
U - 93
Z « -0.0681 p - 0.943
Unpaired T-Test
Set Name Mean SD SEM N
12 CA+ 2 OX 0.14 0.05 0.02 5
16 CA- 2 OX 0.18 0.05 0.02 5
F ratio — 1.0560 fl - 4 f2 - 4 p >=o.:
Assuming Equal Variance : T - 1.2050 DF = 8 p
Assuming Unequal Variance : T = 1.2050 DF = 8 p
Mann Whitney U Test.
Data from Column 12 and 16 including Row 1 to 134
Data set 1 CA+ 2 OX N - 5
Data set 2 CA- 2 OX N = 5
0 = 8





3 CA+ 1 CI 2.37
7 CA- 1 CI 1.25
F ratio - 2.2630 fl
Assuming Equal Variance :




20 f2 - 8 p >-0.1
T - 2.2217 DF - 28 p - 0.035
T - 2.6094 DF - 23 p - 0.016
Mann Whitney U Test.
Data from Column 3 and 7 Including Row 1 to 134
Data set 1 CA+ 1 CI N - 21
Data set 2 CA- 1 CI N - 9
U = 40
Z - -2.4687 p - 0.014
Unpaired T-Test
Set Name Mean SD SEM N
11 CA+ 2 CI 2.05 1.83 0.82 5
15 CA- 2 CI 4.15 2.59 1.16 5
F ratio - 2.0057 fl - 4 f2 - 4 p >-0.1
Assuming Equal Variance : T — 1.4794 DF — 8 p — 0.177
Assuming Unequal Variance : T — 1.4794 DF — 7 p — 0.183
Mann Whitney U Test.
Data from Column 11 and 15 including Row 1 to 134
Data set 1 CA+ 2 CI N - 5
Data set 2 CA- 2 CI N - 5
U - 5























fl 56 f2 — 19 p >-0.1
s T - 4.0377 DF - 75 p <0.001
: T - 4.3536 DF = 39 p <0.001
Mann Whitney U Test.
Data from Column 16
Data set 1 24CA 1






p - < 0.001
Row 1 to 134
Unpaired T-Test
Set Name Mean
32 CA 1/CR 0.6977
34 CA 1K/CR 0.4081
F ratio - 6.6187 fl
Assuming Equal Variance :







45 f2 — 19 p <0.01
T - 2.7285 DF - 64 p - 0.008
T - 3.6929 DF - 64 p <0.001
Mann Whitney U Test.
Data from Column 32
Data set 1 CA 1/CR






p - < 0.001
Row 1 to 134
FREQUENCY DISTRIBUTION - 24 HR URINE CALCIUM (MMOLS)
(Control Mean + 2 S.D. - 10.44)
93
Data from column* 16 to 16 and rowa 1 to 134




0| 1 1 * 1 y 1 ♦ 1 H 1 f 1 + 1 ► 1
0.00 5.22 10.44 15.66 20.88 26.10 31.32 36.54 41.76
MALES
Data from column a 17 to 17 and rowa 1 to 134
X™Cla*a dimanaiona Y-Numbara in elaaaaa
10-
01 ¥ 1 ♦ 1 f 1 i |—+ 1 + 1 + 1 f j
0.00 5.22 10.44 15.66 20.88 26.10 31.32 36.54 41.76
MALE CONTROLS
FREQUENCY DISTRIBUTION - URINE CALCIUM/CREATININE RATIO
(Control Mean + 2 S.D. » 0.765)
Date from columns 32 to 32 and rows 1 to 134








, 1 1 1 ► 1 * 1 ► 1 h 1 ♦ 1 ► 1
00 0.38 0.76 1.15 1.53 1.91 2.29 2.67 3.C
MALES
Data from columns 34 to 34 and rows 1 to 134




—, * , ► 1 ► 1—
1.15 1.53 1.91 2.29
MALE CONTROLS




Set Name Mean SD SEM N
18 24CA 2 5.9161 3.4215 0.6466 28
19 24CA 2 K 2.8554 1.5603 0.3185 24
F ratio = 4.8084 fl =27 f2 - 23 p <0.01
Assuming Equal Variance : T = 4.0333 DF « 50 p <0.001
Assuming Unequal Variance : T = 4.2462 DF — 39 p <0.001
Mann Whitney U Test.
Data from Column 18 and 19 including Row 1 to 134
Data set 1 24CA 2 N = 28
Data set 2 24CA 2 K N = 24
U - 139
Z = -3.6167 p - < 0.001
Unpaired T-Test
Set Name Mean SD SEM N
33 CA 2/CR 0.5791 0.3162 0.0707 20
35 CA 2K/CR 0.3224 0.2120 0.0433 24
F ratio « 2.2254 fl = 19 f2 - 23 p >=0.1
Assuming Equal Variance : T — 3.2089 DF « 42 p - 0.003
Assuming Unequal Variance : T = 3.0973 DF ■ 32 p " 0.004
Mann Whitney U Test.
Data from Column 33 and 35 including Row 1 to 134
Data set 1 CA 2/CR N - 20
Data set 2 CA 2K/CR N - 24
U - 119
Z = -2.8520 p = 0.004
FREQUENCY DISTRIBUTION - 24 HR URINE CALCIUM
(Control Mean + 2 S.D. - 5.98)
Dot:a from column* 18 to 18 and row* 1 to 134













I*** *** *** *** ***
0| + 1 + 1 y 1 +—I y—I y—I—+—I y—|
0.00 5.98 11.96 17.94 23.92 29.90 35.88 41.86 47.84
FEMALE STONE FORMERS
Data from columns 19 to 19 and rows 1 to 134




01—+— I + 1 —+ 1 + |™+ 1 K I + 1 +— I
0.00 2.99 5.98 8.97 11.9( 14.95 17.94 20.93 23.92
FEMALE CONTROLS
FREQUENCY DISTRIBUTION - 24 HR URINE CALCIUM/CREATININE RATIO
(Control Mean + 2 S.D. - 0.746)
Oat.* from oolumna 33 to 33 and rows 1 to 134




01 Y 1 + 1 Y 1 + 1 ¥ 1 Y | + 1 ♦ 1
0.00 0.50 1.00 1.50 2.00 2.50 3.00 3.50 4.00
FEMALE STONE FORMERS
Data from columns 35 to 35 and rows 1 to 134





01 + I + 1 ► 1 ♦ I 1 1 + I ♦ , y 1
0.00 0.S0 1.00 1.S0 2.00 2.SO 3.00 3.50 4.00
FEMALE CONTROLS




Set Name Mean SD SEM N
20 24UR 1 4.5386 1.4994 0.2004 56
21 24UR 1 K 2.7115 1.4293 0.3196 20
F ratio - 1.1004 fl - 55 f2 - 19 p >-o.:
Assuming Equal Variance : T - 4.7336 DF - 74 p
Assuming Unequal Variance : T - 4.8435 DF - 35 p
Mann Whitney U Test.
Data from Column 20 and 21 including Row 1 to 134
Data set 1 24UR 1 N - 56
Data set 2 24UR IK N - 20
U - 193
Z = -4.3294 p - < 0.001
Unpaired T-Test
Set Name Mean SD SEM N
36 UR 1/CR 0.3664 0.1751 0..0261 45
38 UR 1K/CR 0.2505 0.1389 0..0311 20
F ratio - 1.5894 fl - 44 f 2 - 19 p >-o.:
Assuming Equal Variance : T - 2.6130 DF - 63 P
Assuming Unequal Variance : T - 2.8564 DF - 46 P
Mann Whitney U Test.
Data from Column 36 and 38 including Row 1 to 134
Data set 1 UR 1/CR N - 45
Data set 2 UR 1K/CR N - 20
U - 268
Z - -2.5869 p - 0.010
FREQUENCY DISTRIBUTION - 24 HR URINE URATE
(Control Mean + 2 S.D. ~ 5.56)
Data from columns 20 to 20 and rows 1 to 134
X™Clasa dimansions Y-Numbsrs in classss
► | + 1 ► 1 + | ► 1 h 1 + 1 1- 1
0.00 2.78 8.34 11.12 13.90 14.88 19.48 22.24
MALE STONE FORMERS
Data from oolumns 21 to 21 and rows 1 to 134
X«Cla*s <Hmansions Y*Numbars in olassas
lO-
OI ¥ 1 + 1 ► 1 1- 1 V 1 ¥ 1 ¥ 1 ► 1
0.00 2.78 5.58 8.34 11.12 13.90 18.88 19.48 22.24
MALE CONTROLS
FREQUENCY DISTRIBUTION - 24 HR URINE URATE/CREATININE RATIO
(Control Mean + 2 S.D. «■ 0.528)
Data from columna 36 to 36 and rows 1 to 134











0.79 1.06 1.32 1.58 1.85 2.11
MALE STONE FORMERS
Data from columns 38 to 38 and rows 1 to 134








| | 4-—— | +——— |—-1 | ♦ 1 —-f——— |
0.26 0.53 0.79 1.06 1.32 1.58 1.85 2.11
MALE CONTROLS





Set Name Mean SD SEM N
22 24UR 2 3.4036 1.3054 0.2611 25
23 24UR 2 K 3.4279 1.4937 0.3049 24
F ratio = 1.3092 fl - 23 f2 - 24 p >—0.1
Assuming Equal Variance : T - 0.0607 DF - 47 P ~ 0.952
Assuming Unequal Variance : T - 0.0606 DF - 46 P " 0.952
Mann Whitney U Test.
Data from Column 22
Data set 1 24UR 2







Row 1 to 134
Unpaired T-Test
Set Name Mean SD SEM N
37 OR 2/CR 0.3935 0.1674 0.0406 17
39 UR 2K/CR 0.3540 0.1129 0.0231 24
F ratio - 2.1962 fl 16 f2 - 23 p >-0.01 & p <0.05
Assuming Equal Variance : T - 0.9039 DF - 39 p - 0.372
Assuming Unequal Variance : T - 0.8464 DF - 26 p - 0.405
Mann Whitney U Test.
Data from Column 37
Data set 1 UR 2/CR







Row 1 to 134
FREQUENCY DISTRIBUTION - 24 HR URINE URATE
(Control Mean + 2 S.D. - 6.40)
102
Data fro* ooluana 22 to 22 and rows 1 to 134













— | + 1 H 1 + I —-+ 1 ► I + 1 ——f 1
1.40 3.20 4.80 €.40 8.00 9.€0 11.20 12.80
FEMALE STONE FORMERS
Data from columns 23 to 23 and rowa 1 to 134
X»Claaa diaanaiona Y-Nuabar# in olaaaaa
0| ► 1




FREQUENCY DISTRIBUTION - 24 HR URINE URATE/CREATININE RATIO
(Control Mean + 2 S.D. - 0.580)
Data froa oolumns 37 to 37 and rows 1 to 134



















*** *** *** *** *** *** *** ***
1 1 1 1—-4 1 1 1- ™+ 1 ► 1 4 1 ► 1
0.50 0.70 0.97 1.1C 1.36
FEMALE STONE FORMERS
Data from oolusna 39 to 39 and rows 1 to 134





0 I ► 1 4 1—4 1 4—1 *■ 1 ► 1 • 1 ► 1
0.00 0.19 0.39 0.50 0.70 0.97 1.1C 1.30 1.55
FEMALE CONTROLS






24 240X 1 0.2131
26 240X 1 K 0.2285
F ratio - 1.0436 fl -
Assuming Equal Variance :




46 f2 - 19 p >-0.1
T - 0.4973 DF - 65 p - 0.621
T - 0.5017 DF - 37 p - 0.619
Mann Whitney 0 Test.
Data from Column 24 and 26 including Row 1 to 134
Data set 1 240X 1 N - 47
Data set 2 240X IK N - 20
0 - 397
Z - -1.0003 p - 0.317
Unpaired T-Test
Set Name Mean SD SEM N
40 OX 1/CR 0.0168 0.0085 0.0012 47
42 OX 1K/CR 0.0198 0.0080 0.0018 20
F ratio - 1.1361 fl - 46 f2 - 19 p >-o.:
Assuming Equal Variance : T - 1.3431 DF - 65 p » 0.184
Assuming Unequal Variance : T - 1.3786 DF - 38 p - 0.176
Mann Whitney U Test.
Data from Column 40
Data set 1 OX 1/CR







Row 1 to 134
FREQUENCY DISTRIBUTION - 24 HR URINE OXALATE
(Control Mean + 2 S.D. - 0.456)
105
Data from columa 24 to 24 and rows 1 to 134
X^lua dinansions Y—Numbars in da
12-
** *** ***
f 1 h 1 ► 1 + | H 1 1 | + 1 ► 1
00 0.15 0.30 0.46 0.61 0.76 0.91 1.06 1.2
MALE STONE FORMERS
Data fro* column* 26 to 26 and rows 1 to 134












** •** *** ***
01 ♦ J ► 1 ¥
0.00 0.15 0.30
— I ► I + 1 • 1






FREQUENCY DISTRIBUTION - 24 HR URINE OXALATE/CREATININE RATIO
(Control Mean + 2 S.D. « 0.04)
Data from columns 40 to 40 and rows 1 to 134






h 1 + 1 f 1 * 1—-f 1 h | — — I ► 1
0.03 0.04 0.05 0.06 0.07
MALE STONE FORMERS
Data from columns 42 to 42 and rows 1 to 134
X"Class dimensions Y—Numbers in classes
10-
k** *** ***
► | ♦ | ► | ♦ | V | h | ♦ 1 ► |
00 0.01 0.02 0.03 0.04 0.05 0.06 0.07 0.C
MALE CONTROLS












Assuming Equal Variance :










23 f2 - 20 p >-0.01 & p <0.05
T - 1.3830 DF - 43 p - 0.174
T - 1.4247 DF - 39 p - 0.162
Mann Whitney U Test.
Data from Column 25
Data set 1 240X 2







Row 1 to 134
Unpaired T-Test
Set Name Mean SD SEM N
41 OX 2/CR 0.0201 0.0081 0.0018 21
43 OX 2K/CR 0.0240 0.0118 0.0024 24
F ratio - 2.0941 fl - 23 f2 - 20 p >—0.1
Assuming Equal Variance : T - 1.2706 DF - 43 p - 0.211
Assuming Unequal Variance : T - 1.3016 DF - 41 p — 0.200
Mann Whitney U Test.
Data from Column 41
Data set 1 OX 2/CR







Row 1 to 134
FREQUENCY DISTRIBUTION - 24 HR URINE OXALATE
(Control Mean + 2 S.D. - 0.497)
108
Data from columns 25 to 25 and rows 1 to 134









»■ 1 * 1 ► 1 1 1 1- 1 ► 1-
0.30 0.40 0.50 0.60 0.70
FEMALE STONE FORMERS
h—|
Data from oolumns 27 to 27 and rows 1 to 134






0| ► | + 1 ►-
0.00 0.10 0.20
"I * 1 ► 1 ► 1 + 1 ► 1
0.30 0.40 0.50 0.60 0.70 0.60
FEMALE CONTROLS
FREQUENCY DISTRIBUTION - 24 HR URINE OXALATE/CREATININE RATIO
(Control Mean + 2 S.D. - 0.048)
109
Data from ooluana 41 to 41 and rows 1 to 134










1 , + 1 ► , + 1 ► 1 ► |- ♦ 1 y 1
0.03 0.04 0.05 0.06 0.07 0.08
FEMALE STONE FORMERS









► | + 1 f 1 + 1 + 1 f— | +
00 0.01 0.02 0.03 0.04 0.05 0.06
FEMALE CONTROLS
►—I
























fl 19 f2 - 46 p >-0.05 & p <0.1
: T = 0.1960 DF - 65 p - 0.845
: T - 0.1792 DF - 30 p - 0.859
Mann Whitney U Test.
Data from Column 28
Data set 1 24CIT 1







Row 1 to 134
Unpaired T-Test
Set Name Mean SD SEM N
44 CT/CR 1 0.1921 0.1307 0.0191 47
46 CT/CR IK 0.2062 0.1226 0.0274 20
F ratio - 1.1362 fl - 46 f2 - 19 p >—o.;
Assuming Equal Variance : T - 0.4109 DF - 65 p - 0.683
Assuming Unequal Variance : T - 0.4217 DF - 38 p - 0.676
Mann Whitney U Test.
Data from Column 44
Data set 1 CT/CR 1







Row 1 to 134
FREQUENCY DISTRIBUTION - 24 HR URINE CITRATE
111
Data from columns 28 to 28 and rows 1 to 134





oloo 1!20 2!40 3! 60 4ls0 «!oO 1.20 8'.40 9! 60
MALE STONE FORMERS
Data from columns 30 to 30 and rows 1 to 134




01 —+— I + 1 f 1 1 1 f 1 V— I + 1 V 1
0.00 1.20 2.40 3.60 4.80 6.00 7.20 8.40 9.60
MALE CONTROLS
FREQUENCY DISTRIBUTION - 24 HR URINE CITRATE/CREATININE RATIO
Data from column# 44 to 44 and rows 1 to 134












—♦ | + 1 ¥ 1 H | h 1 — , H 1 »■ 1
0.48 0.44 0.80 0.94 1.12 1.28
MALE STONE FORMERS
Data from columns 44 to 44 and rows 1 to 134
X-Class dimensions Y-Numbers la classes
i** *** *** *** a*
0.48 0.44 0.80 0.94
MALE CONTROLS












Assuming Equal Variance :




23 f2 - 20 p >-0.05 & p <0.1
T - 2.0980 DF - 43 p - 0.042
T - 2.1360 DF - 42 p - 0.039
Mann Whitney U Test.
Data from Column 29 and 31 including
Data set 1 24CIT 2 N - 21
Data set 2 24CIT 2K N - 24
U - 168




45 CT/CR 2 0.2596
47 CT/CR 2K 0.4403
F ratio - 2.2011 fl
Assuming Equal Variance t










23 f2 - 20 p >-0.01 & p <0.05
T - 2.5164 DF - 43 p - 0.016
T - 2.5816 DF - 41 p - 0.014
Mann Whitney U Test.
Data from Column 45 and 47 Including Row 1 to 134
Data set 1 CT/CR 2 N - 21
Data set 2 CT/CR 2K N - 24
U - 155
Z - -2.2068 p - 0.027
HR URINE CITRATE
FREQUENCY DISTRIBUTION - 24 HR URINE CITRATE/CREATININE RATIO
115
Data from columns 45 to 45 and rows 1 to 134










► 1 f 1 + 1 ». 1 +■ , f , ». 1 + 1
0.44 0.80 0.96 1.12 1.28
FEMALE STONE FORMERS
Data from columns 47 to 47 and rows 1 to 134






24 HR URINE CITRATE/CREATININE RATIO - (MALE CONTROLS Vs FEMALE CONTROLS)
Unpaired T-Test
Set Name Mean SD SEM N
46 CT/CR IK 0.2062 0.1226 0.0274 20
47 CT/CR 2K 0.4403 0.2781 0.0568 24
F ratio - 5.1444 fl - 23 f2 - 19 p <0 .01
Assuming Equal Variance : T - 3.4861 DF - 42 P
Assuming Unequal Variance : T - 3.7119 DF - 33 P
Mann Whitney U Test.
Data from Column 46
Data set 1 CT/CR IK







Row 1 to 134
24 HR URINE CITRATE/CREATININE RATIO - (After dalation of all values < 0.16)
(FEMALE STONE FORMERS £ CONTROLS)
Unpaired T-Test
Set Name Mean SD SEM N
45 CT/CR 2 0.3800 0.1272 0.0353 13
47 CT/CR 2K 0.5202 0.2305 0.0515 20
F ratio - 3.2833 fl 19 f2 - 12 p >-0.01 £ p <0.05
Assuming Equal Variance t T — 1.9980 DF - 31 p - 0.055
Assuming Unequal Variance : T — 2.2455 DF — 30 p — 0.032
Mann Whitney U Test.
Data from Column 45 and 47 Including Row 1 to 134
Data set 1 CT/CR 2 N - 13
Data set 2 CT/CR 2K N - 20
U - 81
FREQUENCY DISTRIBUTION - 24 HR URINE CITRATE/CREATININE RATIO
(After deletion of values <0.16)
118
Data from columns 45 to 45 and rows 1 to 134













, + , f 1 f , + ,
0.64 0.80 0.96 1.12 1.28
FEMALE STONE FORMERS
Data from oolumns 47 to 47 and rows 1 to 134







24 HR URINE CITRATE (MMOLS)
119
After deletion of patients whose Calcium or Urate




28 24CIT 1 2.3745
30 24CIT IK 2.2810
F ratio - 1.3974 fl
Assuming Equal Variance t




17 f2 - 29 p >-0.1
T - 0.2182 DF - 46 p - 0.828
T - 0.2091 DF - 31 p - 0.836
Mann Whitney U Test.
Data from Column 28 and 30 including Row 1 to 134
Data set 1 24CIT 1 N - 30
Data set 2 24CIT IK N - 18
0 - 250
Z - -0.4259 p - 0.669
120
FREQUENCY DISTRIBUTION
24 HR URINE CITRATE (MMOLS) - After deletion of patients whose Calcium or Urate
or Oxalate was > (control mean + 2 S.D.)




































4.80 6.00 7.20 8.40 9.60
MALE STONE FORMERS
Data from column* 30 to 30 and row*


























24 HR URINE CITRATE/CREATININE RATIOS - (MALE STONE FORMERS and CONTROLS)
After deletion of patients whose Calcium or Urate










Assuming Equal Variance t







27 f2 - 18 p >-0.1
T - 0.4221 DF - 45 p - 0.675
T - 0.4446 DF - 44 p « 0.659
Mann Whitney U Test.
Data from Column 44 and 46 including Row 1 to 134
Data set 1 CT/CR 1 N - 28
Data set 2 CT/CR IK N - 19
U - 220
Z - -0.9972 p - 0.318
122
FREQUENCY DISTRIBUTION
24 HR URINE CITRATE/CREATININE RATIO -
After deletion of patients whose Calcium or Urate
or Oxalate was > (control mean + 2 S.D.)
Data from columns 44 to 44 and rows 1 to 134





I*** *** *** *** *** ***
I*** *** *** *** *** ***
0| ► 1 + 1 h 1 + | h 1 h 1 * 1 ► 1
0.00 0.16 0.32 0.40 0.64 0.80 0.96 1.12 1.28
MALE STONE FORMERS
Data from columns 46 to 46 and rows 1 to 134





is** *** *** *** •** ***
0 j ► 1 ♦ 1 + 1 f 1 * | ► 1 ► 1 * 1
0.00 0.16 0.32 0.48 0.64 0.80 0.96 1.12 1.28
MALE CONTROLS
24 HR URINE CITRATE <MMOLS) - (FEMALE STONE FORMERS and CONTROLS)
Aftar delation of patients whose Calcium or Urate
















Assuming Equal Variance :
Assuming Unequal Variance i
21 f2 - 15 p <0.01
T - 3.5671 DF - 36 p - 0.001
T - 3.8958 DF - 34 p <0.001
Mann Whitney U Test.
Data from Column 29
Data set 1 24CIT 2







Row 1 to 134
124
FREQUENCY DISTRIBUTION
24 HR URINE CITRATE (MMOLS) -
After deletion of patients whose Calcium or Urate
or Oxalate was > (control mean + 2 S.D.)

































f ! + 1 > 1 + I ^ 1 y 1 + 1 y 1
2.00 4.00 4.00 4.00 10.00 12.00 14.00 14.00
FEMALE STONE FORMERS
Data from columns 31 to 31 and rows 1 to 134
X"CIass dimensions Y"Numbers In ola
0 | ► 1 ♦ | * 1 -—► 1 —♦ 1 ► 1—f | ♦ 1
0.00 2.00 4.00 6.00 8.00 10.00 12.00 14.00 14.00
FEMALE CONTROLS
24 HR URINE CITRATE/CREATININE RATIOS - (FEMALE STONE FORMERS and CONTROLS)
After deletion of patients whose Calcium or Orate
or Oxalate was > (control mean + 2 S.D.)
Unpaired T-Test
Set Name Mean SD SEM N
45 CT/CR 2 0.2156 0.1742 0.0450 15
47 CT/CR 2K 0.4659 0.2730 0.0582 22
F ratio - 2.4557 fl 21 f2 - 14 p >-0.01 & p <0.05
Assuming Equal Variance : T — 3.1352 DF - 35 p — 0.003
Assuming Unequal Variance : T — 3.4030 DF - 35 p — 0.002
Mann Whitney 0 Test.
Data from Column 45 and 47
Data set 1 CT/CR 2
Data set 2 CT/CR 2K
0 - 73
Z - -2.8460 p - 0.




24 HR URINE CITRATE/CREATININE RATIO -
After deletion of patients whose Calcium or Urate
or Oxalate was > (control mean + 2 S.D.)
Data froa colu 45 to 45 and towa 1 to 134











0| y—I ► 1 * 1 y 1 ►—I y—I y—I H 1
0.00 0.14 0.32 0.46 0.44 0.80 0.94 1.12 1.28
FEMALE STONE FORMERS
Data froa ooluana 47 to 47 and tow* 1 to 134
X^laaa dinanaiona Y~Numb*ra in claaaaa
0| ► 1


















CITRATE/CREATININE RATIO (FEMALE STONE FORMERS and CONTROLS)
After exclusion of patients with urine Calcium or Orate














24 HR URINE CITRATE (MMOLS) (FEMALE STONE FORMERS)
Pre-menopausal ( < 50 yrs) ▼ Postmenopausal ( > 50 yrs)
Unpaired T-Test
Name
24 CIT 2 (>50)





24 HR URINE CITRATE (M40LS) (FEMALE CONTROLS)
Pre-menopausal ( < 50 yrs) v Postmenopausal ( > 50 yrs)
Unpaired T-Teat



















Set Name Mean SD SEM N
48 CT/CA 1 0.3311 0.3511 0.0518 46
50 CT/CA IK 0.5728 0.3545 0.0793 20
F ratio - 1.0193 fl - 19 f2 - 45 p >-0.1
Aaauming Equal Variance : T - 2.5630 DF — 64 p - 0.013
Aaauming Unequal Variance : T - 2.5532 DF — 36 p — 0.015
Mann Whitney U Teat.
Data from Column 48
Data aet 1 CT/CA 1







Row 1 to 134
Unpaired T-Teat
Set Name Mean
49 CT/CA 2 0.5010
51 CT/CA 2K 2.0729
F ratio - 42.6996 fl
Aaauming Equal Variance :




23 f2 — 19 p <0.01
T - 3.2119 DF - 42 p
T - 3.5104 DF - 24 p
0.003
0.002
Mann Whitney U Teat.
Data from Column 49
Data aet 1 CT/CA 2






p - < 0.001
Row 1 to 134




Set Name Mean SD SEM N
52 CT/OX 1 14.5578 11.4390 1.6685 47
54 CT/OX IK 15.0263 16.3444 3.6547 20
F ratio - 2.0416 fl 19 f2 - 46 p >-0.i
Assuming Equal Variance : T — 0.1343 DF — 65 p — 0.894
Assuming Unequal Variance : T — 0.1166 DF — 27 p — 0.908
Mann Whitney U Test.
Data from Column 52
Data set 1 CT/OX 1







Row 1 to 134
Unpaired T-Test
Set Name Mean SD SEM N
53 CT/OX 2 15.3965 12.7767 2,.7881 21
55 CT/OX 2K 26.8951 24.8368 5,.0698 24
F ratio - 3.7788 fl 23 f2 - 20 p <0..01
Assuming Equal Variance : T - 1.9101 DF - 43 P " 0.063
Assuming Unequal Variance : T - 1.9874 DF - 35 P " 0.055
Mann Whitney U Test.
Data from Column 53
Data set 1 CT/OX 2







Row 1 to 134




Set Name Mean SD SEM N
60 CaO/Cil 0.0907 0.1106 0.0163 46
62 CaO/CilK 0.0681 0.0956 0.0214 20
F ratio - 1.3361 fl 45 f2 - 19 p >-0.1
Assuming Equal Variance : T = 0.7949 DF - 64 p - 0.430
Assuming Unequal Variance : T - 0.8421 DF - 42 p - 0.405
Mann Whitney U Test.
Data from Column 60 and 62 including Row 1 to 134
Data set 1 CaO/Cil N - 46
Data set 2 CaO/CilK N - 20
U - 336
Z - -1.7301 p - 0.084
Unpaired T-Test
Set Name Mean SD SEM n
61 CaO/Ci2 0.0885 0.1133 0.0253 20
63 CaO/Ci2K 0.0525 0.1060 0.0216 24
f ratio - 1.1416 fl - 19 f2 - 23 p >-o.:
Assuming Equal Variance : T - 1.0894 DF - 42 p - 0.282
Assuming Unequal Variance : T - 1.0828 DF » 39 p - 0.286
Mann Whitney U Test.
Data from Column 61 and 63 including Row 1 to 134
Data set 1 CaO/Ci2 N - 20
Data set 2 CaO/Ci2K N - 24
U - 122
Z - -2.7813 p - 0.005







F ratio - 5.6741 fl -
Assuming Equal Variance :




45 f2 - 19 p <0.01
T - 1.4477 DF - 64 p - 0.153
T - 1.9282 DF - 64 p - 0.058
Mann Whitney U Test.
Data from Column 56
Data set 1 CaOx/Crl












F ratio - 1.2011 fl
Assuming Equal Variance :




23 f2 - 19 p >-o.;
T = 1.6626 DF - 42 P
T - 1.6768 DF - 42 P
Mann Whitney U Test.
Data from Column 57
Data set 1 CaOx/Cr2







Row 1 to 134





Set Name Mean SD SEM N
64 CU/CtCrl 2.2019 3.4328 0.5117 45
66 CO/C.C1K 0.8959 1.4315 0.3201 20
F ratio - 5.7507 fl 44 f2 - 19 p <0.01
Assuming Equal Variance : T ~ 1.6336 DF — 63 p — 0.107
Assuming Unequal Variance : T — 2.1636 DF • 63 p ■ 0.034
Mann Whitney 0 Test.
Data from Column 64
Data set 1 CU/CtCrl






p - < 0.001
Row 1 to 134
Unpaired T-Test
Set Name Mean SD SEM N
65 CU/CtCr2 2.1718 3.7174 0..9016 17
67 CU/C.C2K 0.7526 1.5014 0..3065 24
F ratio « 6.1305 fl - 16 f2 - 23 p <0..01
Assuming Equal Variance : T - 1.6923 DF - 39 P
Assuming Unequal Variance : T - 1.4904 DF - 20 P
Mann Whitney U Test.
Data from Column 65
Data set 1 C0/CtCr2







Row 1 to 134























































































Variance about regression 2.4554




























Variance about regression 6.0355
X" 24CR IKY" 24CA X K 4—Data points i">l point *"<o»t-£it straight line
10.2200- +
♦ 4
1.22004 1 1 1 1 1
4.2000 0.5000 10.8000 13.1000 15.4000 17.7000



























Variance about regression 19.1353
Correlation 24 HR ORINE ORATE : 24 HR ORINE CREATININE (MALE CONTROLS)
Column Name
X data: 21 240R 1 K
Y data: 13 24CR 1 K
Correlations-0.008 N- 20
T » 0.0337
. DF» 18 p- 0.973







































Variance about regression 7.4931





4.3000 1 ♦—I 1 1 1
0.1600 1.6100 3.0600 4.5100 5.9600 7.4100



























Variance about regression 1.9060
X» 24UK 2 K Y- 24CR 2 K +-D*t* point* *«>1 point *-Boot-fit straight lino
12.4700- + +
6—+ I 1 1 1 1
1.2200 2.2220 3.2240 4.2260 5.2260 6.2300




























Variance about regression 19.8962



























Variance about regression 3.9056



























Variance about regression 5.3671




4.3000-4- 1 1 1 | 1
0.1000 1.6380 3.1760 4.7140 6.2520 7.7800



























Variance about regression 9.7440


































Variance about regression 2.1440



























Variance about regression 2.3320



























Variance about regression 2.0269





1 4.3000 7.6000 10.0000 14.2000 17.5000
t
3.0160-



























Variance about regression 0.0171
X* CA 1/CR Y" UR 1/CR point.* *->1 point. straight lina
0.0971 0.€729 1.2487 1.9245 2.4004 2.9762



























Variance about regression 1.0744






































Variance about regression 0.0219
X" CA 2/CR Y- UR 2/CR -W>ata point# 4">1 point *«Ba»t-£it straight lino
0.7129- ♦
0.1639-
0.1667 0.3625 0.5583 0.7540 0.9498 1.1456



























Variance about regression 1.6935



























Variance about regression 7.3767



























Variance about regression 1.9743


































Variance about regression 2.1886




0.1000 4—f 1—f 1 1 1 1
1 3.9000 € 8.5000 11 13.5000






























Variance about regression 0.0808




























Variance about regression 0.0177





























Variance about regression 0.0141




























Variance about regression 0.0248
X» CA 2/CR Y" CT/CR 2 -f—Doto point.* *->1 point *"Bo»t-£it straight lino
0.6082- ♦ +
0.1667 0.3625 0.5583 0.7540 0.9498 1.1456



























Variance about regression 2.5720



























Variance about regression 2.0391





























Variance about regression 0.0312
Correlation CITRATE/CREATININE RATIO : ORATE/CREATININE RATIO
(MALE CONTROLS)
Column Name
X data: 46 CT/CR IK
Y data: 38 OR 1K/CR
Correlation- 0.190 N- 20
T - 0.8227 DF- 18 p- 0.421










Variance about regression 0.0196



























Variance about regression 1.8842



























Variance about regression 2.3126

























































Variance about regression 0.0133
1
ARTERIAL BLOOD GASES IN STONEFORMERS (MALE and FEMALE)




(MALE and FEMALE COMBINED)
Calculations by Column:Including Rows 1 - 134
Column Name Mean S.D. S.E.M. Coef.V N
2 H+ 40.48 2.89 0.45 7.14 42
Calculations by Column:Including Rows 1 - 134
Column Name Mean S.D. S.E.M. Coef.V N
3 pC02 5.12 0.44 0.07 8.58 42
Calculations by Column:Including Rows 1 - 134
Column Name Mean S.D. S.E.M. Coef.V N
4 HC03 23.80 1.85 0.29 7.79 42
Calculations by Column:Including Rows 1 - 134
Column Name Mean S.D. S.E.M. Coef.V N
5 p02 11.63 1.60 0.25 13.78 42
(ARTERIAL HCO, FEMALE)
Calculations by Column:Including Rows 1-29
Column Name Mean S.D. S.E.M. Coef.V N
4 HC03 23.0833 1.8195 0.5252 7.8823 12
(ARTERIAL HCO, MALE)
Calculations by Column:Including Rows 56 - 113
Column Name Mean S.D. S.E.M. Coef.V N
4 HC03 24.0833 1.8198 0.3323 7.5564 30
























































Variance about regression 0.0096



























Variance about regression 4.7378
X* 14 Y- 24CXT 2 points *->1 point *"N«t-fit atmight lino
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Variance about regression 1.3164
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Variance about regression 0.0091
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Variance about regression 3.1163




































Variance about regression 0.0235




Correlation CITRATE/CREATININE RATIO : ARTERIAL HCO, (FEMALE STONE FORMERS)


























Variance about regression 0.0157
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Correlation 24 HR URINE CITRATE s ARTERIAL HCO, (MALE STONE FORMERS)
After exclusion of patients with urine Calcium or Urate





























Correlation CITRATE/CREATININE RATIO : ARTERIAL HCO, (MALE STONE FORMERS)
After exclusion of patients with urine Calcium or Urate





























Variance about regression 0.0107
Correlation 24 HR URINE CITRATE ! ARTERIAL HCO, (FEMALE STONE FORMERS)
After exclusion of patients with urine Calcium or Urate



























Variance about regression 1.4631
*• HC03 Y- 24CXT 2 points *->1 point *»Bost-£it straight lino
3.9900- ♦
Correlation CITRATE/CREATININE RATIO s ARTERIAL HCO+ (FEMALE STONE FORMERS)
After exclusion of patients with urine Calcium or Orate






























BC03 Y- CT/CR 2 ♦Hktt point* •«■»! point *"loot-fit ftraifht lino
0.0400—
10.5000 19.0000 21.1000 22.4000 23.7000
SERUM CREATININE (MALE STONE FORMERS Vs FEMALE STONE FORMERS)
Unpaired T-Test
Set Name Mean SD SEM N
7 S.CREAT1 103.38 16.12 2.85 32
8 S.CREAT2 82 13.26 3.68 13
F ratio - 1.4782 fl 31 f2 - 12 p >-0.1
Assuming Equal Variance : T - 4.2264 DF - 43 p <0.001
Assuming Unequal Variance : T — 4.5941 DF — 27 p <0.001



























Variance about regression 1.88
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Variance about regression 0.02
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Variance about regression 2.49
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5.43- +
Correlation SERUM CREATININE s CITRATE/CREATININE RATIO (FEMALE STONE FORMERS)
Column Name
X data: 7 SE.CREAT
Y data: 45 CT/CR 2
Correlation—0.667 N— 9
T - 2.37 DF- 7 p- 0.050
Regression slope «■ -9.02514E-03
Y-intercept — 0.98




Variance about regression 0.02
X" 31 .CJUtXT Y- CT/CR 2 ♦—Onto points *">1 point straight lino
0.04 1 1 ► 1 1 1
99 <7.20 79.40 03.(0 91.00 100
Discussion:
This study involving adult stone formers and
controls from East Central Scotland allows us to draw
several important conclusions about Nephrolithiasis in
this region in particular which, it is hoped, might be
applicable to stone formation in other geographical
regions although this is not certain. The aim of this
project was to discover whether simple, non-invasive
investigative procedures which could be incorporated into
an outpatient screening program for stone formers, would
provide meaningful information about the nature and
underlying cause for Urolithiasis in a given individual.
If this were so, then appropriate advice on diet,
lifestyle or medication could be given in order to reduce
or prevent recurrent stone formation.
While some of the ground has been covered by other
workers in the past it is hoped that with the help of
modern investigative techniques and learning from the
inadvertent errors of my predecessors that the methods
and analyses carried out in this study are appropriate
and valid and that the consequent conclusions will be
both statistically as well as clinically sound.
In this study, renal biopsies of stone formers show
the presence of microcalcification in 60% of cases
examined, those in the cortex of the kidney being either
within the tubular lumina or within the tubular cells
themselves. There was a reduced prevalence (23%) of
microcalcification noted in the control samples. This is
in broad agreement with the earlier work by Boyce et al
where a similar picture was found in Calcium Oxalate
stone formers whereas no calcification was found in
biopsies from other types of stone former. Boyce also
showed a gradient of microcalcification increasing from
cortex towards the medulla culminating in the formation
of a Randall's type plaque in the region of the papillae.
In our study as only a single biopsy was taken it was not
possible to demonstrate such a gradient.
With regard to our urinary excretion studies we have
shown definite hypercalciuria in both male and female
stone formers compared with controls and if the upper
limit of normal is taken as " control mean + 2 S.D.", we
find significantly elevated Calcium excretion in 20% of
male stone formers and, perhaps surprisingly, in almost
40% of female stone formers. Whether this reflects an
abnormal dietary predilection for dairy products amongst
our stone formers, abnormal intestinal absorption of
Calcium or so called " renal Calcium leak" is not within
the scope of this study. However, the physical chemical
studies on Calcium Oxalate lithiasis in urine support the
belief that high urinary Calcium excretion predisposes to
crystal nucleation and aggregation, thought to be the
first steps in stone formation.
As far as urinary Urate excretion was concerned
again a marked degree of hyperuricosuria was demonstrated
in male stone formers compared with controls but no such
difference was evident in the female stone former
population. Several workers in the past have also noted
this finding in Calcium Oxalate stone formers and have
drawn " cause and effect" conclusions from this
association alluding to either the putative process of
epitaxy (Coe) or claiming Urate interfered with the
inhibitory action of Glycos-aminoglycans (Pak).
Furthermore, some workers seem to have demonstrated a
reduction in long term stone formation and urinary
oxalate excretion as a result of Allopurinol treatment
(Scott 1989), although a recently published paper claims
that this effect is dietary rather than drug mediated
(Urivetsky 1990).
In this study we have demonstrated a marked positive
correlation between Hypercalciuria and Hyperuricosuria in
male stone formers; it is not therefore possible to
conclude from our results that the finding of
hyperuricosuria in Calcium Oxalate stone formers is
aetiologically significant. It may be for example that
particularly our male stone formers have a diet rich in
both meat and dairy produce resulting in urine rich in
both Calcium and Urate; raised urinary Urate might
therefore be incidental rather than causal.
The urinary Oxalate excretion pattern in this study
population proved to be somewhat surprising there being
no apparent difference between either male or female
stone formers and controls. Urine specimens were
preserved in acid de novo and therefore should not have
been compromised by contamination or ascorbate
interference. The analyses were performed in one of the
premier Oxalate laboratories in the country under the
supervision of Dr G.A. Rose, it would seem unlikely
therefore that the low values could be attributed to
technical problems. In addition our control subjects
showed an upper limit of normal (Control mean + 2 S.D.)
of 0.456 for males and 0.498 for females which agree with
other data from the same laboratory as well as from other
centres. It would seem therefore that in this group of
stone formers from East Central Scotland, Hyperoxaluria
is not a feature but why this should be so remains a
matter for conjecture. Perhaps there is a high dietary
intake of dairy produce in Scottish stoneformers which
results in both absorptive hypercalciuria and binding of
Oxalate in the gut, with consequent reduction in urinary
Oxalate. The urinary Citrate excretion data in some ways
provide the most interesting results from this study. It
is known that Citrate is excreted by the kidney into the
urine in health and both in vivo and in vitro experiments
have confirmed that it has a major role to play as an
inhibitor of Calcium Oxalate and Calcium Phosphate
crystal formation and aggregation. Conditions or
circumstances therefore which limit the production of
Citrate by the kidney would predispose to recurrent stone
formation. Recognition of this entity in stone formers
who have no other identifiable cause for stone disease
should suggest a method of prophylaxis against further
stone formation. It is known that in female control
subjects between the ages of the menarche and the
menopause the urinary Citrate excretion is significantly
greater than is found in the adult male control
population and this finding was confirmed in this series
also. This in itself may partially explain why so called
"idiopathic" stone formation is more common in males and
the effect is thought to be oestrogen related. In our
stone forming patients, while there was no difference in
Citrate excretion between males and controls (when either
24 hr. excretion values or Citrate/Creatinine ratios were
examined), there was a significant reduction in Citrate
excretion amongst our female stone forming patients
compared with controls and this was seen both when 24 hr.
urinary excretion data as well as Citrate/Creatinine
ratios were examined. We have also shown that by
excluding patients with abnormally high urine Calcium,
Urate or Oxalate, that the difference between female
stoneformers and Controls becomes much more significant
(p = 0.004). It may be therefore that this manoeuvre
separates two distinct stoneforming populations, those
with abnormal Calcium, Urate or Oxalate Metabolism, and
those in whom Hypocitraturia is the sole abnormality.
It is known that Citrate excretion is depressed in
conditions of renal impairment and metabolic acidosis
such as renal tubular acidosis (RTA). Low levels of urine
Citrate have also been observed in the presence of
urinary infection as well as spuriously when non
preserved 24hr urine collections for Citrate analysis are
contaminated prior to analysis. This knowledge has cast
some doubt on the conclusions of earlier workers where
adequate sample preservation, exclusion of patients with
renal impairment, and stratification for sex was not
rigorously carried out. In this study all 24hr urine
collections were acidified with Hydrochloric Acid prior
to collection, therefore bacterial contamination should
not have been significant and as a group our stone
formers had no history of urinary infection, nor was
there any clinical evidence of renal impairment.
All stone formers who gave consent, underwent
arterial blood gas sampling and this showed a significant
correlation of Citrate excretion with arterial
bicarbonate in the female stone forming population
suggesting an association between low urinary Citrate
excretion and metabolic acidosis. This would be
consistent with a degree of RTA in this population
however it was not possible to perform Ammonium Chloride
tests to clarify this point with certainty. In an attempt
to further refute the possibility that those patients
with low Citrate excretion had resulted from infection or
contamination those patients with a Citrate/Creatinine
ratio < 0.16 were deleted and the remainder once more
correlated with arterial bicarbonate data. This second
calculation showed there was no longer a significant
correlation. As a result of the non-Gaussian nature of
the Citrate data for both stone formers and controls in
this series it is not possible to define how many stone
formers wefe in fact outwith the "normal range " (control
mean -2 S.D.) however Menon (1983)in a similar study has
defined the lower limit of normal Citrate excretion as
being 1.0 mmol per 24hrs in females and 0.6 mmol per 24
hrs in males. It is interesting to examine the Citrate
data for both males and females after deletion of
patients with an identifiable abnormality that might
predispose to stone formation, namely, significantly
elevated urinary Calcium, Urate or Oxalate. Significantly
low values for Citrate excretion (less than 1.0 mmol per
24hrs) are found in 37.5% of remaining female stone
forming patients and in 10% of male stone formers (less
than 0.6 mmol per 24hrs.) In this present series, in the
female stone forming group, the expected negative
correlation of urinary Citrate excretion with serum
creatinine was demonstrated. Although all our stone
formers had normal renal function as evidenced by serum
Creatinine estimation it may be that in this group of
stoneformers there is a sub-clinical degree of renal
impairment sufficient to affect Citrate production and
acid/base balance. Somewhat against this argument is the
observation that serum Creatinine levels were higher in
male stone formers yet they showed no evidence of low
Citrate excretion or of a any correlation between the two
values. Clearly, therefore, Citrate metabolism in the
female stoneformers of this study is different from males
for another reason. One could speculate that they are
perhaps insensitive to the effects of Oestrogen, which in
normal subjects is associated with relatively higher
levels of excretion of Citrate in the urine, which might
account for low Citrate values and a tendency to stone
formation in this population.
In conclusion therefore this project comparing the
renal biopsy appearances and urinary biochemistry of
stone formers with controls has confirmed firstly, the
presence of significant microcalcification in the
biopsies of stone formers. This finding is in keeping
with other workers and consistent with the model of stone
formation which postulates an initial biochemical event
within the renal tubular cell or tubular urine of the
stone forming kidney.
In this series also a number of pathological
abnormalities were noted on renal biopsy particularly in
those demonstrating microcalcification, further
supporting the theory that an anatomical or pathological
lesion of the tubule may cause impaired tubular
metabolism e.g. Citrate secretion and so initiate
calculus formation. In addition, significant urinary
abnormalities in this group of patients include
hypercalciuria and associated hyperuricosuria in males
and both hypercalciuria and hypocitraturia in females,
although these latter "stone promoting" findings in
female stoneformers occurred in separate sub groups. (In
fact overall there was a positive correlation between
Calcium and Citrate excretion in female stoneformers.)
From a therapeutic or prophylactic viewpoint clearly
increasing fluid intake to around 3 litres per day should
be of benefit to all stone formers. Male stone formers in
whom hyperuricosuria is found, where this is thought to
be a significant factor in stone formation could be
treated with Sodium Bicarbonate to increase their urinary
pH and hence the solubility of Urate, or alternatively
with the Xanthine Oxidase inhibitor, Allopurinol.
The female stone formers with significantly low
levels of urinary Citrate can also be treated by urinary
alkalinisation therapy using either Sodium Bicarbonate or
a mixture containing Potassium Citrate. In the large
group of patients, both male and female in whom
persistent hypercalciuria and recurrent stone formation
is found despite adequate fluid intake, specific
treatment with a Thiazide diuretic can be offered to
reduce the urinary Calcium levels by increasing Calcium
resorption in the distal collecting tubule of the kidney.
This should be used, however, in the knowledge that the
resultant hypokalemia may itself cause further reduction
in Citrate excretion. It would be sensible to monitor
Citrate excretion if long term diuretic therapy was
contemplated and if necessary prescribe supplements of
Potassium Citrate.
Despite the tremendous advances made in the surgical
treatment of established renal calculi, with laudable
emphasis on minimally invasive surgical techniques and
extracorporeal Lithotripsy, there remains the problem of
recurrent stone formation and the plight of the
stoneformer crippled by repeated attacks of colic due to
passage of non-surgical stones. It is hoped that this
Thesis will encourage continuing investigation and
treatment of causal abnormalities for this condition so
that in the future "minimally invasive surgery" may
evolve to "no surgery required".
" Superficially it might be said that the function
of the kidneys is to make urine; but in a more considered
view one can say that the kidneys make the stuff of
philosophy itself. "
from Fish to Philosopher, Ch.l
Homer W. Smith (1895-1962)
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